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The Glu318Gly Substitution in Presenilin 1 Is Not
Causally Related to Alzheimer Disease
To the Editor:
With 49 different mutations in the coding region, pre-
senilin 1 (the gene is denoted “PSEN1”; the protein is
denoted “psen1”) is the most frequently mutated gene
in early onset (onset age !65 years) Alzheimer disease
(AD [MIM 104300]) (Sherrington et al. 1995; Cruts and
Van Broeckhoven 1998). PSEN1 missense mutations are
generally considered fully penetrant mutations. Mostly
they are found in patients with a positive family history
of early-onset AD compatible with autosomal dominant
inheritance. Patients carrying the same mutation usually
display very similar onset ages (Van Broeckhoven 1995).
An ArG transition at codon 318 in exon 9 of PSEN1,
resulting in the nonconserved GlurGly substitution, has
been reported, by us (Cruts et al. 1998) and others
(Sandbrink et al. 1996; Forsell et al. 1997), in familial
AD cases with onset ages of 35–64 years (Cruts and Van
Broeckhoven1998). However, segregation of Glu318Gly
with AD could not be demonstrated, because either no
or too few relatives were available for DNA testing.
PSEN1 Glu318Gly involves the last codon of exon 9
and is located in the middle part of the sixth hydrophilic
loop of psen1. Because of the high variability in onset
age of AD and the mutation’s location in a psen1 region
that is less conserved between psen homologues in hu-
man and other species, we previously had hypothesized
that the Glu318Gly could be either an incompletely pen-
etrant mutation or a rare polymorphism (Cruts and Van
Broeckhoven 1998).
To evaluate the frequency of Glu318Gly and its con-
tribution to AD, we screened incident and prevalent de-
mented cases and age- and sex-matched controls derived
from the Rotterdam Study. This is a prospective single-
center population-based study of elderly residents >55
years of age who are from a Rotterdam suburb (Hofman
et al. 1991). Cognitive functioning was assessed and di-
agnosis of dementia made on the basis of the DSM-III-
R definition (American Psychiatric Association 1987).
Possible and probable AD was diagnosed according to
the National Institute of Neurological and Communi-
cative Disorders and Stroke (NINCDS)–Alzheimer’s
Disease and Related Disorders Associations criteria
(McKhann et al. 1984). Vascular dementia was diag-
nosed according to NINCDS–Association Internationale
pour la Recherche et l’Enseignement en Neurosciences
criteria (Roman et al. 1993). At baseline, 474 prevalent
demented cases were diagnosed (Ott et al. 1995). During
follow-up, another 146 incident cases of dementia were
detected (Ott et al. 1998). From 345 prevalent cases,
134 incident cases, and 256 controls, blood samples
were available for DNA extraction. Controls were ran-
domly selected among nondemented participants in the
Rotterdam Study and were group matched on the basis
of age (5-year intervals) and sex. To facilitate rapid
screening for Glu318Gly, we developed a mismatch PCR
assay that allows detection by BstNI digestion of the
mismatch PCR product. The forward mismatched
primer was 5′-ATCCAAAAATTCCAAGTATAATCC-
AG-3′ and the reverse primer was 5′-CTGGGCAT-
TATCATAGTTCTCAAG-3′.
PSEN1 Glu318Gly was observed in 2 (1.5%) incident
and 11 (3.4%) prevalent demented cases and in 9 (4.1%)
controls. In contrast to previous reports, we detected
Glu318Gly in individuals who were elderly. The fre-
quencies in incident and prevalent cases versus those in
controls were compared by the Fisher exact test and were
found to be not significantly different ( andP 5 .22
, respectively). Of 13 demented Glu318Gly car-P 5 .65
riers, 10 were diagnosed with AD (4 possible AD and
6 probable AD), 1 with dementia associated with Par-
kinson disease, 1 with vascular dementia, and 1 with
dementia associated with multiple sclerosis. Mean age
at onset in demented Glu318Gly carriers (83.4 5 4.7
years, range 72–88 years) was similar to that in de-
mented noncarriers ( years, range 52–9781.0 5 7.7
years). Cognitive functioning measured by the mini-men-
tal state examination in the control group was similar
in Glu318Gly carriers ( ) and noncarriers26.4 5 2.9
( ). Since the e4 allele of apolipoprotein E27.0 5 2.0
(APOE) is known to increase risk for AD (Pericak-Vance
and Haines 1995), we also examined the APOE geno-
types in the demented cases. However, the APOE*e4-
allele frequency in the demented Glu318Gly cases (19%)
was not different from that in the total group of de-
mented cases (21%), excluding a possible interaction
between APOE*e4 and Glu318Gly. Together, these find-
Letters to the Editor 291
ings demonstrate that Glu318Gly is a rare allele (22
carriers/676 individuals, allele frequency 1.6%) in the
Dutch population analyzed and that its presence is not
associated with AD or dementia in general.
The relatively high frequency of Glu318Gly in the
Dutch population analyzed may be explained if all sub-
jects are distantly related. To test this possibility, we
genotyped several polymorphic DNA markers located
within and near PSEN1 (Cruts et al. 1995, 1998). All
Glu318Gly carriers (cases and controls) shared one allele
for D14S77 (203 bp; frequency 8%), the PSEN1 pro-
moter (allele T; frequency 12%), and intron 8 poly-
morphisms (allele A; frequency 54%). Allele sharing was
also observed at D14S1028, with 20 of 22 Glu318Gly
carriers sharing the same allele (239 bp; frequency 4%).
No obvious sharing of alleles was observed at
D14S1004. Frequencies of the shared alleles were cal-
culated in 118 control individuals coming from the same
Rotterdam suburb (C. M. van Duijn, unpublished data).
The probability of detecting this allele combination in-
dependently in 22 cases ( ) strongly suggests2354 # 10
that all Dutch Glu318Gly carriers have one common
founder. Glu318Gly is also frequently observed in pop-
ulations of different geographic and ethnic origins
(Baker et al. 1998; Forsell et al. 1998; Helisalmi et al.
1998; Mattila et al. 1998; Reznik-Wolf et al. 1998; Tor-
res et al. 1998).
The mechanism by which mutations in PSEN1 lead
to AD remains largely unknown. However, an increasing
amount of in vivo and in vitro evidence suggests that
the mutated psen1 expresses its pathogenic effect by pro-
cessing the amyloid precursor protein (APP) in such a
way that increased levels of the 42-amino-acid form of
the amyloid b peptide (Ab42) are secreted (Hardy 1997).
Ab42 is believed to be pathogenic, since it is more prone
to aggregation and therefore leads to accelerated amy-
loid b accumulation in the brain of patients with AD.
To assess whether Glu318Gly also influences APP pro-
cessing, we measured Ab42 levels in conditioned media
of HEK-293 cells stably transfected with the Glu318Gly
PSEN1 cDNA, using an Ab42-specific enzyme-linked
immunosorbent assay (De Strooper et al. 1998). No in-
crease in Ab42 secretion was observed, compared with
cell lines stably transfected with wild-type PSEN1
cDNA. The absence of increased APP processing into
Ab42 in vitro is consistent with our findings at the pop-
ulation level, which show no association of Glu318Gly
with either AD or dementia.
A few possibilities remain unexplored. First, since we
detected the Glu318Gly allele only in the heterozygous
state, it cannot be excluded that Glu318Gly is associated
with dementia in an autosomal recessive manner. How-
ever, there is no evidence supporting autosomal recessive
inheritance in familial AD (Rao et al. 1994). The fact
that neither none of 479 late-onset patients screened in
the present study nor the 100 early-onset cases screened
in earlier studies (Cruts et al. 1998) carried two copies
of the allele makes it unlikely that homozygosity for
Glu318Gly is a frequent cause of AD. Another as yet
not excluded possibility is that all Glu318Gly carriers
share a (disease) phenotype that is different from either
AD or dementia and that has remained undetected in
the present study. However, we are not aware of any
nondementia phenotypes associated with genetic varia-
tions in PSEN1.
In conclusion, we provide evidence that PSEN1
Glu318Gly is not causally related to either AD or other
types of dementia. The latter has important implications
for genetic counseling, since Glu318Gly carriers are not
at increased risk. Our observations also imply that care
should be taken in assigning a pathological nature to
mutations in PSEN1, when these mutations are reported
in isolated cases or in familial cases but in the absence
of conclusive evidence for cosegregation with the disease.
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p53 Variants Predisposing to Cancer Are Present in
Healthy Centenarians
To the Editor:
Cancer results from the expansion of cell clones that
progressively lose control of proliferation, differentia-
tion, and death, owing to accumulation of mutational
events in genes that control the cell cycle and apoptosis.
Nuclear protein p53 is thought to play a major role in
malignancy, since it induces genes that determine apop-
tosis and cell-cycle arrest, interacts with proteins em-
ployed in DNA repair, and binds to DNA strand breaks.
As expected, somatic mutations in p53 are found in a
variety of human cancers. Mutations are predominantly
inactivating, thus eliminating the “guardian of the ge-
nome” from the proliferating cells. Germ-line mutations
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Table 1
Allelic and Genotypic Frequencies of p53 Codon 72 Polymorphism
No. (%) of
Younger Controls
[ ]n 5 204
No. (%) of
Centenarians
[ ]n 5 176
p53 Allele:a
Pro72 128 (31.4) 101 (28.7)
Arg72 280 (68.6) 251 (71.3)
p53 Genotype:b
Pro72/Pro72 18 (8.8) 12 (6.8)
Arg72/Pro72 92 (45.1) 77 (43.8)
Arg72/Arg72 94 (46.1) 87 (49.4)
NOTE.—Hardy-Weinberg equilibrium (HWE) of p53 genotypes was
assessed by exact tests. Both groups were in HWE: younger controls,
; and centenarians, . x2 tests for comparison of allelicP 5 .46 P 5 .61
and genotypic distributions were performed by use of Monte Carlo
algorithms implemented by means of the Statistical Product and Service
Solutions package.
a , df 1, .2x 5 0.64 P 5 .42
b , df 2, .2x 5 0.74 P 5 .68
of p53 also have been described as the molecular basis
of a rare familial cancer-prone syndrome, Li-Fraumeni
syndrome. At the population level, common variants
(polymorphisms) of p53 are present. In particular, a
CrG transversion leads to a proline-to-arginine change
at p53 codon 72. Several studies have reported data
regarding the association of the codon 72 variants with
susceptibility to a variety of human cancers, such as
breast cancer, lung cancer, and colorectal neoplasia (Bir-
gander et al. 1995; Sjalander et al. 1996). Some reports
suggest that Arg/Pro72 alleles should be considered as
markers in linkage disequilibrium with other sites able
to modulate cancer risk (Sjalander et al. 1995). Recently,
a new insight into the role of codon 72 in human cancers
has been reported by Storey et al. (1998). In their anal-
ysis, the authors found that a majority (76%) of women
affected by human papillomavirus (HPV)–induced cer-
vical carcinoma were homozygous for Arg72 alleles,
compared with a frequency of 37% among unaffected
women. In addition, when functional analysis of p53
variants was performed, the authors found that a p53
protein carrying an arginine at codon 72 binds more
effectively to HPV oncoprotein E6 and is degraded and
inactivated more rapidly by the proteasome pathway.
The result is an estimated sevenfold risk of developing
cervical cancer, for people homozygous for Arg72, when
infected by HPV that is able to produce E6 protein.
Overall, the available data in the literature suggest that
p53 variants may be considered as risk factors for some
of the major neoplastic diseases in humans, such as lung,
colorectal, breast, and cervical cancer, and are expected
to affect survival. Hence, an underrepresentation of p53
variants involved in cancer risk would be expected in a
group of people who reach very old age in good health
and who have escaped any overt cancer disease. Ac-
cordingly, healthy centenarians of both sexes were stud-
ied, to test this prediction, and the results were compared
with those obtained from the study of a group of
younger people.
The centenarians and the controls in our study were
basically those studied in a previous investigation, in
which significant differences in the frequency of apoli-
poprotein B (ApoB) VNTR alleles were found between
the two groups (De Benedictis et al. 1997). The sample
of centenarians comprised 176 healthy unrelated sub-
jects (53 males and 123 females) from northern and
southern Italy, and the health status of each was assessed
as described elsewhere (Capurso et al. 1997). The con-
trol group comprised 204 younger unrelated subjects
(113 males and 91 females, 20–60 years of age) ran-
domly collected from northern and southern Italy. The
ancestry in the specific geographic area of the subjects
included in this study was checked as far back as the
grandparental generation. In table 1 the frequencies of
p53 codon 72 alleles and genotypes in the younger con-
trols and the centenarians are shown. No difference be-
tween the two groups was found. Moreover, no differ-
ence in allelic and genotypic distributions, between the
centenarians and the younger controls, was found when
sex and geographic origin were considered in the analysis
or when the group of younger controls was split into
two subgroups (!40 and ≥40 years of age) (data not
shown).
Several explanations can account for the results re-
ported here. First, the most direct explanation is that
Arg/Pro72 alleles are neutral and do not exert any cen-
soring, with regard to susceptibility to cancer and life
expectancy. This hypothesis is compatible with the cau-
tious conclusions of a recent meta-analysis, which points
out that a consensus about the role of p53 variants in
human cancer has yet to be reached (Weston and God-
bold 1997). Second, we can assume that p53 codon 72
Arg/Pro alleles are not neutral. In view of this hypothesis,
our data on healthy centenarians suggest that the long-
term consequences of p53 codon 72 Arg/Pro alleles on
survival are negligible, even though they are related to
increased cancer risk. However, additional data regard-
ing the incidence of and mortality rate for p53-related
cancers in the cohort studied and the relative risk of
developing these diseases, for different p53 allelic vari-
ants, are needed in order to reject the above-mentioned
hypothesis. On the other hand, recent data indicate that
p53 polymorphisms appear to modulate an individual’s
risk of developing cancer only when peculiar conditions
occur (i.e., a particular viral infection). In this case, only
a small proportion of people who carry certain alleles
would be selectively lost during aging.
However, these considerations probably are quite sim-
plistic, owing to the possibility that the scenario is much
more complex. Indeed, unexpected nonmonotonic age-
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related trends of allele frequency can be found for genes
related to survival and longevity. This is the case for the
ApoB gene (De Benedictis et al. 1998), which we pre-
viously showed to be correlated with longevity (De Bene-
dictis et al. 1997). We recently conceptualized these find-
ings and created a model to account for the complex
changes, with age, observed for ApoB gene allele fre-
quencies (Yashin et al. 1998). According to this model,
complex trajectories can be expected when the existence
of “frail” and “robust” alleles of longevity-associated
genes are assumed and when the mortality rates of the
carriers of the two types of alleles are crossed. A similar
conclusion was reached when changes, with age, in the
allelic frequencies of genes related to cardiovascular risk
factors, such as angiotensin-converting enzyme, were
considered (Schachter et al. 1994).
As far as we know, the above-mentioned models
(Toupance et al. 1998; Yashin et al. 1998) represent the
only theoretical framework available to address the com-
plex problems encountered when biodemographic data
and genetic data, concerning longevity genes and genes
related to risk factors for major age-related diseases, are
merged and compared. A similar model for p53 could
be of great interest and could help in (1) testing the
hypothesis that the p53 Arg/Pro72 alleles are related to
increased cancer risk and (2) answering the question of
whether the frequency of the p53 alleles that we found
in centenarians is compatible with this hypothesis. We
predict that such a model will be quite difficult to de-
velop, given that p53 is involved in a variety of tumors
and that there is a relative paucity of data on p53 allele
frequencies in people of different age groups and, par-
ticularly, in the elderly.
In this regard, if we admit that the data reported here
imply no global differential chance of survival between
p53 genotypes, our results could be due to compensatory
effects. Indeed, opposite effects of genotypes on survival,
at different ages, are predicted by the theory of negative,
or antagonistic, pleiotropy (Williams 1957). The sce-
nario is particularly interesting and challenging with re-
gard to the healthy centenarians, who are the best mod-
els of successful aging and longevity and in whom a
variety of other genetic and nongenetic risk factors for
cardiovascular diseases was found (Mari et al. 1996;
Mannucci et al. 1997; Baggio et al. 1998). Furthermore,
healthy centenarians also can rely on other compensa-
tory mechanisms, such as an effective and well-preserved
immune system, to cope with internal and external
threatening agents (Franceschi et al. 1995).
In conclusion, healthy centenarians may be considered
useful models for testing basic theories on aging. More-
over, this selected group of healthy individuals will be
useful for evaluating the impact of genetic risk factors
on survival and longevity.
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Maternally Inherited Cardiomyopathy: An Atypical
Presentation of the mtDNA 12S rRNA Gene A1555G
Mutation
To the Editor:
Human mitochondrial disorders comprise a heteroge-
neous group of multisystem diseases, characterized by
morphological, biochemical, or genetic abnormalities of
mitochondria. Mutations in mtDNA have been de-
scribed predominantly in a variety of rare encephalo-
myopathies but are also emerging in association with
more common disorders, such as sensorineural hearing
loss (SNHL) and cardiomyopathies (DiMauro and Bon-
illa 1997). Most of the identified mtDNA mutations are
associated with specific clinical phenotypes (DiMauro
and Bonilla 1997). In a recent issue of the Journal, Es-
tivill et al. (1998) reported that the A1555G mutation
in the mitochondrial 12S rRNA is responsible for a sig-
nificant number of cases of maternally inherited non-
syndromic hearing loss and that its pathogenic role is
enhanced by treatment with aminoglycosides.
Idiopathic cardiomyopathies are an important cause
of morbidity and mortality throughout the world, both
in children and adults, with an annual incidence of 2–8/
100,000 in the United States and Europe (Manolio et
al. 1992). The application of molecular genetic tech-
niques has started to delineate the molecular bases of
these syndromes through the demonstration of altera-
tions of myocardial contractile and structural proteins,
such as the cardiac b-myosin heavy-chain (MYH7) gene,
which accounts for ∼75% of the familial cases of hy-
pertrophic cardiomyopathies (Geisterfer-Lowrance et al.
1990). There is growing evidence that mtDNA muta-
tions can cause cardiac disease, including cardiomyop-
athies and cardiac conduction block. In addition,
cardiomyopathy may result from bioenergetic defects
caused by mutations in nuclear-encoded subunits of the
respiratory chain or in nuclear genes controlling the in-
tegrity, replication, and expression of mtDNA (Corto-
passi et al. 1992; Kelly and Strauss 1994; DiMauro and
Bonilla 1997).
We report here a 35-year-old woman who was eval-
uated because of heart failure. At age 23–24 years, dur-
ing her first pregnancy, the patient noted easy fatigability,
shortness of breath, and palpitations. Chest x-ray re-
vealed cardiomegaly with prominent left-atrial enlarge-
ment. Cardiological evaluation suggested a restrictive
cardiomyopathy. Episodes of atrial fibrillation and flut-
ter required cardioversion on several occasions. Four
years later, her clinical condition worsened during a sec-
ond pregnancy. While in sinus rhythm, she was a New
York Heart Association class I-II patient but when in
atrial arrhythmia she worsened to class III. A clinical
and metabolic work-up for heart transplantation was
performed. Family history was remarkable for the
mother and maternal grandmother, who had both died
of unspecified heart diseases in their late 30s. A 25-year-
old brother had a childhood heart murmur but was free
of cardiac symptoms. The proposita’s two daughters are
asymptomatic at ages 11 and 7 years, but the older
daughter had had a cardiac murmur in infancy (fig. 1A).
At age 35 years, physical examination, including neu-
rological and otolaryngeal evaluations, showed a short
and thin woman without other symptoms and signs
commonly found in patients with mitochondrial en-
cephalomyopathy, including ptosis, external ophthal-
moparesis, pigmentary retinopathy, hearing loss, or
diabetes mellitus. A two-dimensional echocardiogram
revealed severe restrictive cardiomyopathy, with mod-
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Figure 1 A, Pedigree of family harboring the A1555G mutation. Arrowhead indicates proband. B, Autoradiogram of the restriction-
length–polymorphism analysis used to quantitate mutant mtDNA. The normal 316-bp PCR-amplified fragment is cut by the endonuclease
Alw26I into two fragments (219 and 97 bp). The A1555G mutation abolishes the Alw26I site. Individuals are as shown in figure 1A. “CTRL”
is a normal control; wbc 5 white blood cells; skin1 5 cultured skin fibroblasts, first passage; skin2 5 cultured skin fibroblasts, second passage;
myo 5 cultured myoblasts; m 5 skeletal muscle.
erate interventricular septum hypertrophy (1.3 mm;
normal !1.0 mm). An endomyocardial biopsy showed
normal myofibrillar array, minimal hypertrophy of
cardiomyocytes, and absence of inflammation. There
were no abnormal deposits of glycogen, iron, or amy-
loid. A diagnosis of idiopathic restrictive cardiomyopa-
thy was made.
After the subjects gave informed consent, we per-
formed our studies under our institutional review
board’s protocol. Skeletal muscle biopsy of the quad-
riceps did not reveal typical mitochondrial abnormali-
ties, such as ragged red fibers or cytochrome c oxidase
(COX)–negative fibers. The most prominent histochem-
ical abnormalities were central or paracentral minicores,
which were easily identified, in many muscle fibers, as
regions of decreased COX stain. Minicores were also
detected by light microscopy in NADH-stained skeletal
muscle sections (fig. 2). Electron microscopy revealed
foci of myofibers with prominent smearing of Z-lines
and absence of mitochondria. Biochemical studies in
muscle homogenate and skin fibroblasts showed slightly
decreased activities of multiple complexes of the respi-
ratory chain when values were normalized to activity of
citrate synthase, a mitochondrial matrix enzyme reflect-
ing total mitochondrial content. Specifically, the residual
activities of NADH-dehydrogenase and COX were 50%
and 39%, respectively, of the mean values measured in
control muscles. PCR followed by SSCP and sequence
analyses of our proband’s muscle mtDNA identified one
possible pathogenic base change, an ArG transition at
nt 1555. By PCR, we amplified all 22 mtDNA-encoded
tRNA genes and did not identify any additional point
mutations by direct sequencing of both strands of the
PCR products. The A1555G mutation was hetero-
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Figure 2 A, NADH-TR stain of the skeletal muscle biopsy. Arrows indicate minicores. B, Abundance of mutated mitochondrial genomes
in normal and abnormal (minicore) fibers, by single-muscle-fiber PCR analysis. The difference is statistically significant ( ).P ! .05
plasmic, accounting for 55% of total muscle mtDNA,
and similar proportions were detected in blood and pri-
mary skin fibroblasts cultures (57% and 60%, respec-
tively). Higher levels of mutated mtDNAs were found
in paraffin sections of an endomyocardial biopsy (89%).
The mutation was present in high percentages in blood
from the two daughters (95% in individual IV-1 and
50% in individual IV-2), the only tissues available for
study (fig. 1B). No additional maternal members of this
family were available for genetic testing.
When we examined the effects of the A1555G mu-
tation on the translational capacity of cultured skin fi-
broblasts in the presence or absence of aminoglycoside
(gentamicin, 0.5 mg/ml), we found moderate protein-
synthesis defects under both conditions. The relative la-
beling ratios and electrophoretic mobility of mitochon-
drial translation products in cell lines harboring 60%
mutated mtDNA did not differ significantly from those
observed in controls in three independent measurements.
However, there was an overall decrease in the rate of
protein labeling, with an average decrease of 35%,
which became more apparent (40%) when aminogly-
coside was added at concentrations used routinely, in
animal cell cultures, to eliminate contaminating micro-
organisms (fig. 3).
Clinically, our patient suffered from a restrictive car-
diomyopathy from early adulthood, with a family his-
tory suggesting maternal transmission, whereas her
brother and one of her daughters had transient valvular
heart disease in early childhood. However, the daughters
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Figure 3 Electrophoretic mobility of the mitochondrial trans-
lation products. Lane 1, III-1 skin fibroblasts (aminoglycoside minus).
Lane 2, III-2 skin fibroblasts (aminoglycoside plus). Lanes 3 and 4,
skin fibroblasts from normal controls. Lane 5, skin fibroblasts from a
disease control harboring a high percentage of the G8363A mtDNA
mutation (Family A, individual III-4, in Santorelli et al. 1996).
remain at risk for cardiomyopathy, because cardiac
symptoms in our proposita did not start until she was
in her early 20s and worsened considerably over the
course of the next 10 years. Likewise, both her mother
and the maternal grandmother died suddenly in their
30s of cardiac failure. We have identified the A1555G
mutation, which we deem responsible for her symptoms,
on the basis of the following considerations. First, the
A1555G mutation was heteroplasmic, both in the pa-
tient and in her maternal relatives. Heteroplasmy, the
coexistence of wild-type and mutated mtDNA molecules
in the same individual, is regarded as an indicator of
pathogenicity, and the abundance of mutated genomes
usually correlates with the severity of the phenotype.
Although this same base change has been associated with
either aminoglycoside-induced deafness (AID) or non-
syndromic hearing loss in several Asian, African, and
Middle Eastern pedigrees, usually in a homoplasmic
state (Prezant et al. 1993), there is evidence of pheno-
typic heterogeneity. Shoffner et al. (1996) have described
a Caucasian family harboring the A1555G mutation, in
association with both SNHL and Parkinson disease, with
onset in middle age. Complex I activity was decreased
in muscle samples of several members of that family, and
the degree of the biochemical defect correlated with the
severity of the clinical phenotype. It is possible that ad-
ditional phenotypes will be associated with this muta-
tion. Second, the clinical expression appears consistent
across three generations of this family, with variations
in age at onset and disease progression, possibly resulting
from differences in proportions and tissue distributions
of mutant genomes. Because the symptoms do not man-
ifest fully until adulthood, individuals IV-1 and IV-2 are
at high risk of developing cardiomyopathy. Third, we
noted a statistically significant correlation between the
abundance of mutated mtDNAs in single muscle fibers
and the presence of “minicores” in our proband (P !
; fig. 2). Whereas minicores and corelike formations.05
have been reported in other myopathies, including nem-
aline myopathy (Afifi et al. 1965) and limb-girdle
dystrophy (Engel et al. 1971), these structural alter-
ations usually are not found in mitochondrial ence-
phalomyopathies. Although the finding of minicores in
our proband’s skeletal muscle may be nonspecific, the
statistically significant association between their pres-
ence and the number of mutated genomes in single fibers
suggests a causal relationship. To the best of our knowl-
edge, no morphological studies in skeletal muscle of pa-
tients harboring the A1555G mutations have been re-
ported. It is also noteworthy that Fananapazir et al.
(1993) reported similar morphological changes in soleus
muscle biopsies taken from patients with hypertrophic
cardiomyopathy as a result of mutations in the MYH7
gene. In those cases, a simultaneous mitochondrial defect
was hypothesized but not examined at molecular genetic
or biochemical levels. Last, our data suggest that the
pathogenetic mechanism of the A1555G mutation in-
volves a primary mitochondrial translation defect, re-
sulting from the base change in the decoding site of the
small ribosome. Cells harboring the A1555G mutation
showed a decreased rate of mitochondrial protein syn-
thesis when compared with controls, even in the absence
of aminoglycoside in the culture medium. Decreased syn-
thesis of the subunits of respiratory complexes is likely
to impair ATP production, with deleterious effects on
cell functions and ultimately resulting in cell death. If
this occurs in cardiomyocytes, it could result in heart
failure, especially during periods of higher metabolic de-
mand, such as pregnancy, as in our patient.
An intriguing issue raised by our report regards the
phenotypic consequences of the A1555G mutation. Phe-
notypic heterogeneity is a common feature of diseases
associated with mtDNA defects and is thought to result
from differential tissue distribution of the mutated ge-
nomes. For example, the A3243G base change in the
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tRNALeu(UUR) gene, although primarily associated with
mitochondrial myopathy, encephalopathy, lactic acido-
sis, and strokelike episodes (MELAS), is also responsible
for other syndromes, such as diabetes mellitus with deaf-
ness, progressive external ophthalmoparesis, and Leigh
syndrome (Shoffner and Wallace 1995). The A1555G
mutation had been long considered an exception to this
rule because it seemed to cause ototoxicity invariably
and exclusively, occurring either spontaneously or after
exposure to aminoglycosides. However, both this report
and the family described by Shoffner et al. (1996)
broaden the clinical spectrum for the A1555G mutation.
The vulnerability of the auditory system has been at-
tributed to the fact that the mutation affects a 12S
rRNA–gene region that is homologous to the aminogly-
coside-binding site of the small rRNA in bacteria. More-
over, the mutation lies within a conserved domain that
in the Escherichia coli 6S rRNA gene forms an essential
part of the decoding site of the ribosome. This region is
crucial for RNA-protein association, RNA-RNA inter-
action, or both; therefore, the mutation could enhance
sensitivity to aminoglycosides in the hairy cells of Corti’s
organ, through defective protein synthesis. Deafness is
not present in our family; however, restrictive cardio-
myopathy is the sole clinical feature, a finding never
before reported.
The fact that many patients with the A1555G mu-
tation have been asymptomatic prior to aminoglycoside
therapy suggests that the mutation alone is functionally
mild (Hutchin et al. 1993). Prezant et al. (1993) hy-
pothesized a “two-hit” model; the 12S rRNA mutation
apparently alters the aminoglycoside-binding site, thus
causing greater susceptibility to the toxic effects of the
drug. In addition, other genetic alterations, perhaps in
nDNA, modify the phenotypic expression of this
mtDNA mutation. Therefore, we cannot exclude the
possibility that, in addition to the abundant mutated
mtDNAs detected in the proband’s heart biopsy, a sec-
ond genetic “hit” may have caused the cardiomyopathy
in our pedigree with the A1555G mutation. By con-
trasting the properties of transmitochondrial cybrids
harboring different percentages of the A1555G muta-
tion from AID patients and from our cardiomyopathy
patient, we may be able to detect biochemical differ-
ences, which could be attributed to a second mtDNA
alteration. As an alternative, nuclear DNA factors—for
example, alterations of a nuclear DNA–encoded mi-
tochondrial ribosomal protein—could modify the phe-
notypic expression of the A1555G mutation.
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An Alu-Mediated 6-kb Duplication in the BRCA1
Gene: A New Founder Mutation?
To the Editor:
Most mutations in the breast/ovarian cancer–predispos-
ing gene BRCA1 that have been identified to date are
point mutations or small insertions and deletions scat-
tered over the whole coding sequence (5,592 nucleotides
long) and over the splice junctions (Breast Cancer In-
formation Core). Although ∼65% are unique, because
of founder effects several mutations have been found in
more than one family, both within specific populations
and in more-diverse geographic groups (Neuhausen et
al. 1996). The other germ-line mutations published so
far are five distinct large deletions (Petrij-Bosch et al.
1997; Puget et al. 1997; Swensen et al. 1997), two of
which represent 36% of all BRCA1 mutations in the
Dutch population (Petrij-Bosch et al. 1997). The im-
portance of such large genomic alterations is difficult to
estimate, because most PCR-based methods that genetic
laboratories use on genomic DNA—such as direct se-
quencing, single-strand conformation analysis (SSCA),
heteroduplex analysis (HDA), denaturing gradient gel
electrophoresis (DGGE), and the protein-truncation test
(PTT)—will not allow their detection.
Here we report the identification of the first large du-
plication in the BRCA1 gene in four apparently unre-
lated families: it comprises exon 13 and extends over 6
kb of intronic sequences. It was initially identified in one
family—F3173—originally ascertained by one of us
(H.T.L.) and contained one case of breast cancer and
four cases of ovarian cancer. Leukocytes of obligate mu-
tation carriers from F3173 had previously been shown
to present a great reduction in the amount of the mutant
transcript, but no alteration was identified in the BRCA1
coding sequence when genomic sequencing and cDNA
SSCA were performed (Serova et al. 1996). No genomic
rearrangement had been found by Southern blot anal-
ysis, and no mutation in the promoter or the 5′ and 3′
UTRs was identified by HDA (Puget et al., in press). To
look for splicing defects, we amplified, with 11 primer
pairs, cDNA synthesized from leukocyte RNA of two
patients from F3173, making sure that each exon was
entirely contained within one fragment. Because we
knew that the mutant allele was poorly expressed, we
considered any abnormal PCR fragment visualized on
agarose gels to be potentially interesting, irrespective of
its intensity. A faint extra band ∼170 bp longer than the
expected fragment was visualized in the case of patients
from F3173 with primers surrounding exons 12 and 13,
which was also seen with primers surrounding exon 13
(fig. 1a). Sequencing of this extra band revealed the pres-
ence of two consecutive exons 13, leading to a frameshift
in the mutant mRNA (ter1460). We then performed
long-range PCR on genomic DNA, with overlapping
primers in exon 13; although, as expected, no PCR prod-
uct was obtained with control DNA, an ∼6-kb fragment
was generated in F3173, indicating that an ∼6-kb du-
plication had occurred in the germ line of the F3173
patient (fig. 1b). The ∼6-kb fragment was then digested
by restriction enzymes, which showed that the dupli-
cation junction was contained within an ∼800-bp XbaI
fragment (fig. 1c). Duplication-specific primers (dup13F/
R) were designed, and a 1.1-kb fragment was PCR am-
plified and sequenced: it revealed that a 6,081-bp region
containing exon 13 (nucleotides 44369–50449 [Gen-
Bank accession number L78833]) is duplicated in F3173
(fig. 1c). Both breakpoints occurred in a 23-bp region
of perfect identity, within two Sx Alu sequences in the
same orientation (86.7% homology)—one in intron 12
and the other in intron 13—which suggests that the du-
plication is probably the result of a homologous recom-
bination.
To evaluate whether this mutation, which may have
previously escaped detection, is present in other families,
we screened, by PCR using primers dup13F/R, 52 ad-
ditional American families ascertained at Creighton Uni-
versity (of which 29 scored negative for mutations in
the coding region and splice sites of the BRCA1 gene
when analyzed by HDA and PTT). This resulted in the
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Figure 1 Characterization of the 6-kb germ-line duplication in the BRCA1 gene in F3173. a, Complementary DNA, which was PCR
amplified with primers 12F (ACA AGC GTC TCT GAA GAC TGC) and 14R (TGC AGA CAC CTC AAA CTT GTC AGC). Only a 318-bp
fragment is generated in the control, whereas in the patient from F3173 a very faint extra band of 490 bp (unblackened arrow) containing two
consecutive exons 13 as determined by sequencing is also produced. b, Genomic DNA, which was PCR amplified with primers 13F (GAT AAA
GCT CCA GCA GGA AAT GGC) and 13R (GGC TCC CAT GCT GTT CTA AC). Only the mutant allele in F3173 gives rise to an ∼6-kb
fragment, shown (unblackened arrow), because the wild-type allele cannot be amplified with these primers (see panel c). c, Duplication of exon
13, schematically represented, with the location and orientation of primers 12F, 14R, 13F, 13R, dup13F (GAT TAT TTC CCC CCA GGC TA),
and dup13R (AGA TCA TTA GCA AGG ACC TGT G). The XbaI sites (X); introns 12 (dotted line) and 13 (broken line); and the position
and extent of the duplicated region, of the 800-bp XbaI fragment generated by the duplication, and of the 6-kb 13F/13R fragment (two-headed
arrows) are indicated.
identification of two more families bearing this dupli-
cation: (1) F3653, which contains seven breast cancer
cases, and (2) F2773, which contains seven breast cancer
cases and three ovarian cancer cases. The three American
families with the duplication are of mixed European
(English, Dutch, or Irish) descent. Finally, the 6-kb du-
plication was also found in one Portuguese family with
three cases of breast cancer, when 69 families (scoring
negative for mutations in the coding region and splice
sites of BRCA1 when analyzed by DGGE [Stoppa-Lyon-
net et al. 1997]) ascertained in Paris by D.S.-L. were
screened. Although these families previously had been
subjected to quantitative Southern analysis (Puget et al.,
in press), this rearrangement was missed because, on the
one hand, the extra bands generated by digestions with
the selected restriction enzymes were identical or very
similar in size to the normal fragments, and, on the other
hand, the densitometric analysis does not allow dupli-
cations to be identified as easily as deletions (1.5-fold
signal-strength difference in duplications, compared
with a 2-fold difference in deletions).
All four families were found to bear exactly the same
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duplication, as revealed by the sequencing of the dupli-
cation junction. A founder effect is very likely, since all
families could share the same haplotype at nine poly-
morphic short tandem-repeat markers within or flanking
the BRCA1locus (D17S776, D17S1185, D17S1320,
D17S855, D17S1322, D17S1323, D17S1327,
D17S1326, and D17S1329). Of the shared alleles, those
at D17S1185 and D17S855 have a population frequency
!15%. Given the geographic diversity displayed by these
four families’ ancestors, the 6-kb duplication might be
relatively old and is therefore likely to be found in other
families around the world. Apart from the two frequent
BRCA1 mutations 185delAG and 5382insC, which have
been found four and five times, respectively, this dupli-
cation is the most frequent mutation identified in the set
of American families ascertained by H.T.L. (3 of 40
BRCA1 mutations).
Although this duplication was identified by reverse-
transcription PCR, it should be noted that it could be
easily missed, since the mutant allele is poorly expressed,
presumably because of premature stop codon–mediated
mRNA decay. Given the high concentration of Alu se-
quences in the BRCA1 gene (Smith et al. 1996), founder
rearrangements such as the one reported here could ex-
plain a substantial fraction of the estimated 37% of
breast/ovarian cancer families whose disease is due to
BRCA1 but for whom no mutation has been identified
so far in the BRCA1 coding sequence (Ford et al. 1998).
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Table 1






Allele 1a Allele 2b
1 10 R1162X 3041-71G/C,c
4002A/Gc
2 14 DF508
3 30 R1162X R117H










13 12 G542X 1716G/Ac
14 32 DF508
15 14 DF508
16 26 N1303K 2622114G/Ac
17 18 DF508 Y301C
18 18 2183AArG
a First mutation found, assigned to one gene.
b Second mutation found, assigned to the gene other
than that to which the first mutation found was assigned.
c Mutation located in allele 1 or allele 2 (no segre-
gation analysis was possible, since the parents were not
available for testing).
d Mutation located in the same gene.
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Cystic Fibrosis Mutations in Heterozygous Newborns
with Hypertrypsinemia and Low Sweat Chloride
To the Editor:
Measurement of immunoreactive trypsinogen concen-
tration (IRT) in dried blood spots is the most common
technique for cystic fibrosis (CF) neonatal screening.
Since a considerable number of newborns show raised
IRT levels, the screening specificity is often improved by
determining whether infants with hypertrypsinemia have
the most common CF mutations: diagnosis is established
in neonates carrying two mutations, but a sweat test is
required if only one mutation is found, to distinguish
between affected individuals—who would have a sec-
ond, unrecognized mutation—and heterozygotes. In-
fants with raised IRT, one CF mutation, and normal
sweat electrolyte concentrations are usually considered
to be carriers only. However, the carrier frequency
among nonaffected IRT-positive babies is almost three
times higher than that in the general population (Laroche
et al. 1991; Castellani et al. 1997); this could be partially
explained if some of these babies carry on the other
chromosome a mild mutation, associated with scarce
symptoms and normal sweat chloride values. A DNA
polymorphic sequence of five thymines (TTTTT) in in-
tron 8 of the CF transmembrane conductance regulator
(CFTR) gene, which is very common in men with a pri-
marily genital CF form called “congenital bilateral
absence of the vas deferens” (CBAVD) (Chillon et al.
1995), has been found to occur more frequently in new-
borns with raised IRT values than in controls (Castellani
et al. 1997; Chin et al. 1997). To look further into the
hypothesis that, in at least some babies, raised trypsin
levels at birth could be a phenotypic expression of a
compound heterozygosity, we investigated a subset of
18 newborns, using the following selection criteria: IRT
199.5 percentile; one identified CFTR mutation among
a panel of 15 mutations that are present in 85% of the
CF chromosomes in our area; normal sweat chloride, as
determined by pilocarpine iontophoresis (mean 16.9
mEq/liter; maximum 32 mEq/liter; minimum 6 mEq/li-
ter). In these neonates and in a control group of 15
healthy subjects (Pignatti et al. 1995), novel and rare
mutations of the CFTR gene were sought by use of a
complete gene search, with denaturing gradient-gel–
electrophoresis analysis of all 27 exons and intronic
flanking regions. PCR products that displayed an altered
behavior in the gel were sequenced after cloning. Seven
CFTR gene mutations were found in eight IRT-positive
newborns, compared with one mutation (L997F) in the
control group ( by Fisher’s exact test; see tableP 5 .02
1). Three of these mutations (R117H, Y301C, and
E527G) are thought to be disease causing in CF or in
CBAVD, since they determine the substitution of an
amino acid in evolutionarily conserved residues and
therefore are tentatively classified, on the basis of the
Cystic Fibrosis Genetic Analysis Consortium (CFGAC)
database, as “mutations”; the other four mutations
(1716 G/A, 2622114 G/A, 3041-71 G/C, and 4002 A/
G) are not believed to be disease causing in CF and
CBAVD, either because they do not determine any amino
acid substitutions (in the case of 1716 G/A and 4002 A/
G) or because they occur in noncoding regions that, as
determined by sequence-analysis software, produce no
apparent alteration (in the case of 2622114 G/A and
3041-71 G/C) and therefore are tentatively classified, on
the basis of the CFGAC database, as CF “polymor-
phisms.” Mutations E527G and 2622114G/A are de-
scribed here for the first time. It is problematic to
understand the clinical significance of the detected
“mutations not supposed to cause CF,” but, as far as
“mutations supposed to cause CF” are concerned, in the
3 (16.6%) of 18 newborns who were compound het-
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erozygous, the raised IRT probably was not a casual
finding but was a biochemical sign of an only partially
functioning CFTR protein. Whether these neonates
ought to be diagnosed as affected with CF is a moot
point. In ∼2% of patients with CF, there is an “atypical”
phenotype, which consists of chronic sinopulmonary dis-
ease, pancreatic sufficiency, and either borderline or nor-
mal sweat chloride concentrations (Rosenstein et al.
1998). Unfortunately, it is not possible at present to pre-
dict the clinical outcome of our newborns, nor is it pos-
sible to provide satisfactory genetic counseling for the
family. A close clinical follow-up should help in clari-
fying the extent of the disease in these subjects.
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A Loss-of-Function Mutation in the Endothelin-
Converting Enzyme 1 (ECE-1) Associated with
Hirschsprung Disease, Cardiac Defects, and
Autonomic Dysfunction
To the Editor:
Hirschsprung disease (HSCR [MIM 142623]) is a con-
genital disorder characterized by an absence of enteric
ganglia over various lengths of the bowel, leading to
functional obstruction and resulting in life-threatening
bowel distension shortly after birth. The incidence is 1
in 5,000 live births. In ∼80% of cases, the rectosigmoid
colon is the only part affected, whereas in 15%–20%
of cases, the aganglionosis extends to the ileocecal junc-
tion. In a small percentage of cases, the entire small
bowel and colon are aganglionic, and in some rare cases,
so-called skip-lesions occur, in which ganglionic and
aganglionic bowel segments alternate.
HSCR is considered to be genetically heterogeneous
(Edery et al. 1994; Puffenberger et al. 1994; Romeo et
al. 1994; Angrist et al. 1996; Edery et al. 1996; Hofstra
et al. 1996; Salomon et al. 1996; Pingault et al. 1998)
and even polygenic (Puffenberger et al. 1994; Angrist et
al. 1996; Salomon et al. 1996; Bolk et al. 1997). Mu-
tations in five genes, RET (Edery et al. 1994; Romeo et
al. 1994), GDNF (Angrist et al. 1996; Salomon et al.
1996), EDNRB (Puffenberger et al. 1994), EDN3 (Ed-
ery et al. 1996, Hofstra et al. 1996), and SOX10 (Pin-
gault et al. 1998) have been shown to give rise, sepa-
rately or in combination (Angrist et al. 1996; Salomon
et al. 1996), to HSCR. They account for 60%–70% of
the familial cases and 10%–30% of the sporadic cases
(R. M. W. Hofstra, unpublished data). Conceivably, mu-
tations in other genes that might be part of the signalling
pathways to which these proteins belong may also lead
to the HSCR phenotype. Here we describe the involve-
ment of one such gene, the gene encoding the endothelin-
converting enzyme I. This enzyme, ECE-1, is involved
in the proteolytic processing of big endothelin 1, 2, and
3, encoded by genes EDN1, EDN2, and EDN3, to the
biologically active peptides, endothelins ET1, ET2, and
ET3, respectively.
For the purpose of the present paper, it is important
to summarize the phenotypes of Edn1, Edn3, and Ece1
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Figure 1 DNA analysis. a, DGGE patterns of exon 19 of ECE-1. A heterozygous variant can be seen in lane 1. Four normal controls
are shown in lanes 2–5. Sequence analysis of b, the normal ECE-1 exon 19 PCR product and c, the exon 19 PCR product of the patient
described. The PCR primers and conditions and DGGE conditions are available upon request.
knockout mice. In Edn11/2 mice, blood pressure is mildly
but significantly elevated, whereas Edn12/2 mice are
characterized by abnormal development of the pharyn-
geal arches, cleft palate, and small mandibula; abnor-
malities in the outflow tract of the heart; and abnormal
thymus and thyroids (Kurihara et al. 1994, 1995). Sim-
ilar abnormalities are also seen in the human DiGeorge
syndrome (MIM 188400). Genetically, however, these
are unrelated, as EDN1 is located on the short arm of
chromosome 6, whereas the locus for DiGeorge syn-
drome is mapped to the long arm of chromosome 22.
Edn12/2 mice die shortly after birth (within hours).
Edn31/2 mice are normal, whereas Edn32/2 mice die
within a few weeks after birth and have pigment anom-
alies and aganglionosis in the distal colon (Baynash et
al. 1994). Similar abnormalities are seen in the human
Shah-Waardenburg syndrome (MIM 277580) (Edery et
al. 1996; Hofstra et al. 1996). Ece11/2 mice are normal,
whereas Ece12/2 mice exhibit neonatal lethality due to
craniofacial and cardiac defects identical to those seen
in Edn12/2 mice. In addition, Ece12/2 newborns lack
enteric ganglia in the terminal colon (Yanagisawa et al.
1998). Thus, Ece1 knockout mice seem to present a
combination of features characteristic for the Edn1 and
Edn3 knockout mice.
These observations prompted us to scan the human
ECE-1 gene (Valdenaire et al. 1995) for mutations in a
patient with skip-lesions HSCR, cardiac defects (ductus
arteriosus, small subaortic ventricular septal defect, and
small atrial-septal defect), craniofacial abnormalities
(cupped ears: immature, and posteriorly rotated; and
small nose with a high bridge and bulbous tip), and other
dysmorphic features (tapered fingers with hyperconvex
nails; a single left palmar crease; contractures at the DIP
joints of the thumbs; PIP joints of the fingers, bilaterally;
and micropenis) and autonomic dysfunction (episodes
of severe agitation in association with significant tachy-
cardia, hypertension, and core temperatures as high as
40.57C; and status epilepticus). The patient had a normal
karyotype without a 22q11 deletion.
We screened all 19 exons of the gene, using denaturing
gradient-gel electrophoresis (DGGE) (GenBank acces-
sion numbers: cDNA sequence, Z35307; exon and in-
tron boundaries, X91922–91939). For DGGE analysis,
a 9% PAA gel (acrylamide-to-bisacrylamide, 37.5:1)
containing a 40%–80% UF (100% M urea andUF 5 7
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Figure 2 Western blot and activity measurements. a, Mutant and native ECE-1b isoforms were transiently transfected into CHO-K1
cells with Lipofectamine (Life Technologies) according to the manufacturer recommendations. Confluent cells in 100 mm plates were harvested
60 h after transfection, and membranes were prepared. Protein levels of expressed ECE-1 were measured on membranes by quantitative
immunoblotting as described (Schweizer et al. 1997). Western blot of one set of transfections is shown: lane 1, nontransfected cells; lane 2,
wild-type ECE-1b; lane 3, R742C mutant; lane 4, R742A. b, ECE-1 activity was assessed by means of a specific radioimmunoassay as described
elsewhere (Schweizer et al. 1997). The results shown are the mean 5 SD of at least three independent experiments, in nanomoles of produced
ET-1 per minute per milligram of ECE-1 protein. C 5 nontransfected cells; WT 5 wild-type ECE-1b.
40% deionized formamide) was used. Electrophoresis
was performed in 0.5# TAE ( mM Tris,1 # TAE 5 40
HAC pH 8.0; 20 mM NaAc; 1 mM Na EDTA) at 11
V/cm and 587C for 18 h. An aberrant DGGE pattern
was detected in exon 19 (fig. 1a). For the analysis of
exon 19, the following primers were used: ECE-1/19F,
5′-ACAGTGACCCTGGCCTCTCC-3′, and ECE-1/19R,
5′-(40-bp GC clamp)TCTCGTCCTCAGCCCCTTCC-
3′. The aberrant PCR products were purified and se-
quenced. A heterozygous CrT transition, resulting in
the substitution of cysteine for arginine at 742, was de-
tected (fig. 1b). Unfortunately, the patient’s parents were
not available for testing. In 100 control individuals, this
mutation was never found. Furthermore, no ECE-1 mu-
tations were found in a further 110 HSCR patients
screened. None of them, however, had the phenotype of
the described patient.
Amino acid position 742 is in the vicinity of the active
site of ECE-1 (Valdenaire et al. 1995). The observed
mutation results in the replacement of a basic amino
acid by a neutral polar amino acid. Moreover, this might
result in the formation of an alternative disulfide bridge.
In humans, three ECE-1 isoforms are generated from the
same gene (Schweizer et al. 1997). They differ only in
their first N-terminal amino acid residues; they share the
same extracellular domain (which includes the enzyme
active site) and cleave big endothelins with similar
efficiencies.
To investigate the functional consequences of the mu-
tation on ECE-1 activity, we introduced it into the hu-
man ECE-1b isoform (Valdenaire et al. 1995; Schweizer
et al. 1997). A PCR approach was used to construct the
mutant (Cys742). Fidelity of the mutants was checked
by sequencing. Wild-type and mutant proteins were pro-
duced by transient expression of the above-described
expression constructs in Chinese hamster ovary cells
(CHO-K1). ECE-1 activity was measured on cell
membrane preparations by means of a specific radio-
immunoassay and quantitative immunoblotting as de-
scribed elsewhere (Schweizer et al. 1997). The specific
ECE-1 activity was calculated as nanomoles of
endothelin 1 produced per minute per milligram of ex-
pressed ECE-1 (nM/min21/mg21). A more detailed pro-
tocol of this functional assay can be found elsewhere
(Lo¨ffler and Maire 1994; Schweizer et al. 1997).
An example of a western blot used for quantitative
immunoblotting is shown in figure 2a. The outcome of
the radioimmunoassay is show in figure 2b. The specific
activity measured in three independent transfections was
for the wild-type ECE-1b, nM/min21/mg21314 5 44
(mean 5 SD), and for the Arg742Cys mutant ECE-1b,
nM/min21/mg21 (mean 5 SD). Thus, the ac-14.7 5 9.8
tivity of the mutant ECE-1 is only 4.7% of that of wild-
type ECE-1. To determine whether this effect was due
to this specific amino acid substitution or more generally
to an effect on the catalytic site, we also generated an
Arg742Ala mutant. This Arg742Ala mutant ECE-1 had
a specific activity of nM/min21/mg21 (mean12.4 5 0.3
5 SD), demonstrating that the position of the mutation
is more important than its specific nature.
In addition, from a developmental point of view, there
are arguments suggesting that the phenotype described
might be caused by reduced activity of the ECE-1 en-
zyme. The vertebrate enteric nervous system is large and
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independent. It develops from cells that migrate to the
gut from three regions of the neural crest. The cells from
the vagal neural crest colonize the enteric bowel below
the rostral foregut, the sacral neural crest cells colonize
only the postumbilical bowel, and the cells of the truncal
neural crest colonize only the rostral foregut primordia
of the esophagus and the cardiac stomach (Gershon
1997). Vagal neural crest cells are also crucial for the
development of the outflow tract of the heart, thymus,
and parathyroid glands. Neural crest cells from more
anterior hindbrain regions play a key role in the pat-
terning of the pharyngeal arches and their derivatives.
The phenotypes in spontaneous and induced Edn3,
EdnrB, and Ece1 mutant mice are all related to the de-
velopmental fate of hindbrain neural crest cells and to
the formation of melanocytes, also derived from the neu-
ral crest.
Further evidence that reduced levels of ET3 might con-
tribute to the development of HSCR comes from ex-
pression studies of this gene in both ganglionic and agan-
glionic colon segments of HSCR patients and control
individuals. Both aganglionic colon and ganglionic colon
of HSCR patients show reduced levels of EDN3 tran-
scripts regardless of the mutation status of genes known
to be involved in HSCR (S. E. Kenny, R. M. W. Hofstra,
Y. Wu, C. H. C. M. Buys, C. Vaillant, D. A. Lloyd, and
D. H. Edgar, unpublished data). This suggests that a low
level of ET3 might be a condition for the development
of HSCR.
In view of (1) the function of ECE-1 during murine
development suggested by the mouse models, (2) the
overlap in phenotypic features of these mouse models
and our patient, and (3) the functional consequences of
the mutation on the enzyme activity, we propose that
the Arg742Cys mutation caused or at least contributed
to the phenotype of our patient by producing reduced
levels of ET1 and ET3.
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Variant Manifestation of Cowden Disease in Japan:
Hamartomatous Polyposis of the Digestive Tract with
Mutation of the PTEN Gene
To the Editor:
Because of the clinical heterogeneity and complexity of
the group of disorders collectively known as inherited
hamartoma syndromes, several attempts have been made
to classify them into distinct categories. In the May issue
of this Journal, Eng and Ji (1998) reviewed recent pro-
gress in molecular characterization of these syndromes
and classified them into four clinical entities: Cowden
disease (CD [MIM 158350]), Bannayan-Ruvalcaba-Ri-
ley syndrome (BRR [MIM 153480]), Peutz-Jeghers syn-
drome (PJS [MIM 175200]), and juvenile polyposis syn-
drome (JPS [MIM 174900]). Despite some progress in
molecular characterization, specific diagnoses of these
disorders remain difficult because their phenotypic spec-
tra overlap and because the penetrance of symptoms is
age related. Clinical syndromic diagnosis is also depen-
dent on many factors, such as the nature and type of
the first clinical symptoms and the medical discipline of
the individual(s) diagnosing the syndrome.
PTEN, a gene mapping to 10q23, encodes a dual-
specificity phosphatase and is also called MMAC1 or
TEP1 (Li and Sun 1997; Li et al. 1997; Steck et al. 1997).
PTEN has been identified as the susceptibility gene for
CD and BRR (Liaw et al. 1997; Marsh et al. 1997), and
it appears that PTEN mutations are detected more fre-
quently in CD and BRR patients when strict clinical
criteria are applied to the selection of test subjects (Liaw
et al. 1997; Marsh et al. 1997, 1998). LKB1/STK11, a
serine threonine kinase gene at 19p13.3, has been iden-
tified as a susceptibility gene for PJS (Hemminki et al.
1998; Jenne et al. 1998). As for JPS, however, some
controversy exists about its molecular basis. Three pos-
sibilities have been raised: (1) germ-line mutations of the
SMAD4/DPC4 gene at 18q21.1 are known to be re-
sponsible for JPS in some affected families (Howe et al.
1998), (2) PTEN mutations appear to be the predis-
posing elements for some patients diagnosed with JPS
(Lynch et al. 1997; Olschwang et al. 1998); and (3) yet
another putative locus (“JP1”), centromeric to PTEN
on chromosome 10q, has been linked to JPS in some
affected families (Jacoby et al. 1997). The low pene-
trance of CD, the sharing of some phenotypic features
between CD and JPS, and the possible genetic hetero-
geneity of JPS make diagnosis complex and confusing.
Pathognomonic hallmarks of CD patients are facial
trichilemmomas, acral keratoses, and verucoid or pap-
illomatous papules. This triad of skin lesions occurs in
99% of CD patients (Hanssen and Fryns 1995; Longy
and Lacombe 1996). Other, less frequent manifestations
of CD include thyroid adenomas or goiters (occurring
in 40%–60% of CD patients), breast fibroadenomas
(70% of affected females), hamartomatous gastrointes-
tinal polyps (35%–40%), and macrocephaly (38%) (Eng
1998; Marsh et al. 1998). JPS is characterized by gas-
trointestinal hamartomatous polyps and an increased
risk of gastrointestinal cancer (Olschwang et al. 1998).
We examined a 35-year-old Japanese man who had
been followed clinically for JPS because of numerous
hamartomatous polypoid lesions throughout the entire
digestive tract, from esophagus to rectum. Although he
had none of the pathognomonic skin lesions of CD, we
extended our clinical examination to the patient’s whole
body and tested him for mutation of the PTEN gene, in
view of Eng’s proposal (1998) that PTEN mutation can
be a useful diagnostic marker for incompletely expressed
CD. After informed consent was obtained, genomic
DNAs prepared from blood from the patient and from
members of his family were examined by direct sequenc-
ing of the entire coding region and exon-intron bound-
aries of PTEN, according to procedures we have de-
scribed elsewhere (Kurose et al. 1998). The patient’s
father died of brainstem infarction, a condition unre-
lated to CD. No other members of his family have been
diagnosed as having CD.
The patient was found to be heterozygous for a GrA
transition at the second nucleotide of codon 130, which
would result in a substitution of Gln for Arg (R130Q).
The patient’s mother and sister did not carry this mu-
tation (fig. 1), nor was it detected in 192 chromosomes
from control Japanese individuals. On closer examina-
tion, which included ultrasonography and computed to-
mography, we found a small thyroid adenoma, a few
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Figure 1 DNA sequencing of the PTEN gene in the family of a patient with variant CD. The patient (blackened square) carries a GrA
transition in exon 5, which is not present in his unaffected mother and sister. Eu: uninformative evaluation.
papillomatous papules in his right hand, and a lung tu-
mor, which is now being examined for possible malig-
nancy. Thus, molecular testing of the PTEN gene, as
proposed by Eng (1998) in another case of suspected
JPS, led us to a diagnosis of CD in a “JPS” patient who
manifested atypical symptoms of CD. His germ-line mu-
tation had occurred in the core motif of the phosphatase,
at amino acid residue 122–132, encoded by exon 5.
Most of the reported germ-line missense mutations of
the PTEN gene reported in patients with CD have oc-
curred within this core motif (Marsh et al. 1998). Thus,
in terms of PTEN mutation, our case is typical of a CD
entity, although the phenotype is atypical.
Eng and Ji (1998) pointed out that apparent “JPS”
patients who carry PTEN germ-line mutations (Lynch
et al. 1997; Olschwang et al. 1998) may in fact belong
to a category of CD patients whose phenotypic features
are only partially expressed. Eng and Ji (1998) proposed
that the presence of a germ-line PTEN mutation could
be a good diagnostic sign for CD and BRR. In the future,
these inherited hamartoma syndromes should be clas-
sified by types of gene mutations, such as the PTEN
mutation syndrome.
The results described here signal the possibility that a
large number of hidden clinical variants of CD may exist
among patients who might have escaped correct clinical
diagnosis and may have been treated for JPS. Our work
underscores the usefulness and importance of molecular
methods for achieving differential diagnoses among pa-
tients with gastrointestinal polyposis, because JPS and
CD predispose to completely different types of cancer.
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Failure to Detect Linkage of Preeclampsia to the
Region of the NOS3 Locus on Chromosome 7q
To the Editor:
Preeclampsia is an important inheritable pregnancy-re-
lated hypertension syndrome. Since it develops as a result
of widespread endothelial dysfunction, the NOS3 gene
responsible for endothelium-derived nitric oxide (NO)
production via its gene product, eNOS, has been sug-
gested as an obvious candidate gene for preeclampsia
(Morris et al. 1996). We were intrigued, therefore, by
the report, by Arngrı´msson et al. (1997), of linkage in
the region of the NOS3 gene and have attempted to
repeat their findings in our own collection of preeclamp-
sia families.
Evidence for linkage was sought by use of two, sep-
arately ascertained, affected sister-pairs (ASPs) collec-
tions, from Amsterdam and Cambridge (United King-
dom), that contained 104 sibships. In the Cambridge
Centre, a total of 21 extended pedigrees were also iden-
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Table 1






Amsterdam ( ):n 5 46
NOS3i13 11.1 20.2 14.6 .250
Cambridge ( ):n 5 58
D7S483 11.3 32.0 14.7 .388
NOS3i13 18.0 28.0 12.0 .584
D7S505 15.1 30.0 13.8 .584
Combined ( ):n 5 104
NOS3i13 28.9 47.8 26.3 .547
Table 2
Results of Computer Simulations with SLINK, for 500 Replicates
MODEL
AVERAGE LOD SCORE AT v 5
.0 .1 .2 .3 .4
AD 6.05 4.89 3.37 1.92 .75
AD/LP 1.70 1.49 .99 .53 .18
AR 4.89 3.81 2.48 1.26 .39
AO 3.88 3.12 2.05 1.08 .37
tified, some on the basis of the ASPs suitable for con-
ventional parametric linkage studies. All affected indi-
viduals were Caucasian and met the Redman and
Jefferies criteria of preeclampsia: they were proteinuric
(1300 mg/24 h) and hypertensive, with a blood pressure
of 1140/90 occurring after 20-wk gestation and with a
>25-mmHg rise in diastolic blood pressure (Redman
and Jefferies 1988). These features all resolved by 3 mo
postpartum, and none of the subjects had concurrent
diabetes, renal disease, or essential hypertension. Some
sibships (!5%) contained subjects showing features of
pregnancy-induced hypertension (PIH) alone (i.e., they
were not proteinuric). These members were not included
in subsequent sib-pair analysis, and none of the larger
pedigrees used contained subjects with PIH. For the pur-
poses of linkage analysis, all males were assigned to the
affection status of “unknown.”
Subjects were genotyped for the CA-repeat marker
within intron 13 of the NOS3 gene (referred to here as
“NOS3i13”). The Cambridge samples were also geno-
typed for the two flanking markers D7S483 and
D7S505. Genotyping was performed by use of PCR am-
plification of the microsatellite markers by means of
primer pairs, in which the forward primer had been 5′
end–labeled with a fluorescent amidite. CEPH primer
sequences were used for the flanking markers, and
primer sequences published elsewhere were used for
NOS3i13 (Nedaud et al. 1994). The PCR products were
multiplexed and were run on an ABI 377, and allele
sizes were determined by use of version 2 of GENO-
TYPER (Applied Biosystems).
The number of alleles shared identical by descent
(IBD) was calculated for the ASPs by use of the maxi-
mum-likelihood method, as implemented in SPLINK
(Holmans 1993; Holmans and Clayton 1995). Parental
genotype data were used where available but were in-
complete for the Cambridge ASPs and were not available
for the Amsterdam ones. Comparison of allele frequen-
cies and marker heterozygosity from the SPLINK output
for the two groups showed no significant differences
between the two collections. The allele sharing for the
NOS3i13 marker is shown in table 1, for both the Am-
sterdam and Cambridge ASPs. There is no evidence of
excess allele sharing in either group. In fact, the Cam-
bridge group shows a deficit of allele sharing, attribut-
able to chance alone. To confirm this, allele sharing for
the two flanking markers for NOS3, D7S483 and
D7S505, was investigated. These two flanking markers
are approximately equidistant from NOSi13 and span
a 4-cM region over 7q36. Again, there was no evidence
of a significant positive deviation from a 1:2:1 distri-
bution in the Cambridge group, either for D7S483 or
for D7S505.
Parametric analysis of the preeclampsia pedigrees was
performed by use of four of the models, employed else-
where (Arngrı´msson et al. 1997), as follows (q is the
frequency of disease gene, and f is the penetrance): an
autosomal model (AD) of high arbitrary penetrance
( , ), a partial-dominance model (AD/LP;q 5 .02 f 5 0.9
, , ), a fully recessive modelq 5 .10 f 5 0.21 f 5 1.0Aa AA
(AR; ), and an affecteds-only model (AO;q 5 .2 q 5
, ). The power of the preeclampsia.02 f 5 f 5 0.001Aa AA
pedigree collection to detect linkage was estimated by
means of simulation of each model, by use of SLINK
(Weeks et al. 1991; Ott 1989). The results of 500 rep-
lications of each model generated by SLINK, if a hy-
pothetical marker with eight equally frequent alleles
( ) is assumed, are summarized in tables 2 andPIC 5 .86
3. These results show that such a marker linked tightly
to preeclampsia provides an average LOD score suffi-
cient to establish linkage in three of the four models.
The power of the simulated marker to detect linkage in
the AD/LP model is substantially less than that of the
other three models, as has been noted elsewhere (Har-
rison et al. 1997).
The models were tested by use of all three markers
for the 4-cM interval, on 7q, encompassing the NOS3
locus. Table 4 shows the results of two-point linkage
analysis, using allele frequencies provided by SPLINK;
the findings were not altered significantly by the assign-
ment of equal allele frequencies throughout. For all the
models, linkage to NOS3i13 could be excluded with
. As expected from the SLINK modeling, theLOD ! 22
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Table 3
Results of Two-Point Linkage Analysis
MODEL
% OF REPLICATES WITH
LOD-SCORE THRESHOLD 1
1 2 3
AD 100.0 99.4 97.6
AD/LP 78.4 41.4 10.8
AR 100.0 98.4 89.2
AO 98.8 89.6 72.4
Table 4
Two-Point Linkage Results for the Four Models Tested
MODEL AND
MARKER
LOD SCORE AT v 5
.00 .01 .05 .10 .20 .30 .40
AD:
D7S505 27.22 25.52 23.01 21.59 2.34 .08 .14
NOS3i13 29.76 28.40 25.41 23.44 21.40 2.46 2.07
D7483 22.37 22.05 21.27 2.80 2.41 2.26 2.15
AD/LP:
D7S505 21.56 21.40 2.90 2.49 2.07 .07 .07
NOS3i13 22.08 21.86 21.20 2.67 2.12 .07 .08
D7483 .34 .39 .51 .53 .39 .17 .02
AR:
D7S505 2` 27.02 23.63 22.08 2.74 2.23 2.04
NOS3i13 2` 27.69 23.98 22.16 2.58 2.04 .07
D7483 2` 23.80 21.46 2.50 .11 .14 .03
AO:
D7S505 23.20 22.51 21.03 2.22 .32 .34 .20
NOS3i13 26.03 25.05 22.92 21.63 2.47 2.06 .04
D7483 21.91 21.59 2.86 2.43 2.13 2.09 2.08
low-penetrance AD/LP model provided smaller LOD
scores than did the other three models, and linkage to
the flanking markers could not be excluded in our pre-
eclampsia pedigrees. However, for neither of the markers
under the AD/LP model did the LOD scores approach
the required threshold of (Kidd and Ott3 1 log (4)
1984).
These results, therefore, have failed to confirm linkage
of preeclampsia to a chromosome 7q 4-cM region con-
taining the NOS3 gene, as reported by Arngrı´msson et
al. (1997). This failure occured despite use of a similar
combination of ASPs and conventional two-point link-
age in pedigrees. Our study used two independently as-
certained collections of ASPs, containing a total of 104
ASPs that appeared to be powered adequately. We have
estimated the ls for preeclampsia at ∼10, assuming a
local prevalence of preeclampsia (using our strict defi-
nition) of some 2%. Since our total ASP collection con-
tains 70 fully informative pairs (estimated by SPLINK)
for the NOSi13 marker, an expected maximized LOD
score of 7.6 is given (Risch 1990). Even if ls has been
overestimated, a figure of 5 would still result in a LOD
score substantially 13 (actually 5.7).
Our inability to replicate the earlier linkage report
could reflect population differences, although both stud-
ies are based on white northern Europeans. It is possible
that significant differences in our definition of the pre-
eclampsia phenotype may be important, although the
differences in our method of ASP analysis seem unlikely.
We have focused in our study only on ASPs with a def-
inite diagnosis of preeclampsia, excluding ones in which
the diagnosis either is uncertain or is consistent only with
isolated PIH. Nevertheless, Arngrı´msson et al. (1997)
report that the significance of the excess allele sharing
was not substantially altered by removal of the milder
phenotypes from the sib-pair analysis. Our method of
sib-pair analysis relies on a maximum-likelihood method
(SPLINK) to calculate allele sharing that is IBD. The
SPLINK program is able to utilize parental genotype
data, although this was not available for most of our
ASPs. The previous linkage study on 7q also used a
likelihood ratio–based method (SIBPAIR), as well as di-
rect testing of increased identity by state (IBS) sharing
(APM). A recent comparison of the various methods
available to detect linkage in nuclear pedigrees, including
sib pairs, showed the superiority of IBD-based programs
versus IBS-based programs (Davis and Weeks 1997). In
this comparison, SPLINK actually showed comparable
power to detect linkage with the SIBPAIR program, ex-
cept when additional genotypes were available from un-
affected members, which was not the case in this study.
Our choice of SPLINK, therefore, is unlikely to have
increased the possibility of a false-negative result.
The previous positive sib-pair analysis reported by
Arngrı´msson’s group was also supported by two-point
linkage results from their pedigree collection (Arngrı´ms-
son et al. 1997). They investigated a number of different
models, reported elsewhere, from the literature. The
LOD score, maximized over the five models, was 4.03,
by use of the D7S505 flanking marker rather than the
NOS3i13 marker. This suggests that the preeclampsia
locus may be some distance away from the NOS3 gene
itself, although the NOS3i13 marker and the preeclamp-
sia locus must be in linkage disequilibrium, on the basis
of their transmission/disequilibrium-test results. Adopt-
ing a similar parametric analysis in our own preeclamp-
sia pedigrees, we have failed to demonstrate a LOD score
high enough to confirm linkage in any of the models. In
fact, the LOD scores generated actually have enabled us
to exclude linkage in all of them, except the AD/LP
model. Using the AD/LP model, we did find a small,
nonsignificant LOD score, using a flanking marker, but
it was by use of D7S483 and not D7S505—that is, at
the opposite end of the 7q interval.
A key role for endothelium-derived NO in pregnancy
is well supported. An eNOS inhibitor, for example, in-
fused chronically into pregnant animals, produces a
preeclampsia-like state, with hypertension, proteinuria,
thrombocytopenia, and growth retardation (Molnar and
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Hertelendy 1992). More-recent findings also provide di-
rect evidence for the role of NO production in the fall
in peripheral vascular resistance (and blood pressure)
seen in normal human pregnancy (Knock and Poston
1996). It is possible that NO forms part of an adaptation
pathway, to accommodate the cardiovascular changes of
pregnancy and to prevent the development of maternal
hypertension and the clinical syndrome of preeclampsia.
However, although these data provide a tantalizing cir-
cumstantial argument for NOS3 being a candidate gene
for preeclampsia, they do not prove that a primary ab-
normality in eNOS underlies the pathophysiology of pre-
eclampsia. It is equally plausible that the observed
changes in NO production during preeclampsia are
secondary to free-radical damage of the vascular
endothelium.
In summary, then, we have been unable to replicate
the previous report of linkage of preeclampsia to the
region of the NOS3 gene. Although abnormalities in NO
production have been observed in preeclampsia, we be-
lieve that the case for the NOS3 gene or its product,
eNOS, having a primary role in the pathophysiology of
preeclampsia remains unproved.
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Exclusion of Chromosome 7 for Kartagener Syndrome
but Suggestion of Linkage in Families with Other
Forms of Primary Ciliary Dyskinesia
To the Editor:
We read with great interest the recent letter by Pan et
al. (1998), in which they report a case of uniparental
disomy, of chromosome 7, associated with cystic fibrosis
(CF), complete situs inversus, and immotile (although
ultrastructurally normal) bronchial ciliary apparatus.
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Table 1












LOD SCORE.00001 .01000 .05000 .10000
D7S531 5.28 212.768 27.357 23.647 22.121 2.01141 .05
D7S517 7.44 212.722 27.056 23.357 21.885 2.01106 .05
D7S513 17.74 213.868 28.068 23.937 22.262 2.01309 .05
D7S507 28.74 28.319 24.576 22.133 21.161 2.00457 .05
D7S493 34.69 28.053 24.332 21.963 21.056 2.00425 .05
D7S629 37.51 29.616 25.046 22.114 21.032 .07877 .20
D7S484 53.50 -9.594 25.027 21.993 2.850 .06800 1.00
D7S519 69.03 25.742 23.035 21.093 2.331 .15600 1.00
D7S502 78.65 29.215 25.308 22.410 21.262 2.00372 .05
D7S669 90.42 24.445 21.861 2.238 .250 .38000 1.00
D7S657 104.86 211.184 26.100 22.916 21.630 2.00768 .05
D7S527 108.59 26.591 23.671 21.763 2.989 2.00445 .05
D7S486 124.08 21.096 2.191 .323 .428 .51927 .55
D7S530 134.55 27.525 23.492 21.162 2.374 .28454 .30
D7S640 137.83 26.547 22.833 2.645 .031 .31760 .60
D7S684 147.22 23.048 21.115 2.041 .249 .28700 1.00
D7S550 178.41 26.711 23.420 21.198 2.437 .04600 1.00
Those authors appropriately suggest that linkage studies
be conducted in families with Kartagener syndrome
(KS), to evaluate chromosome 7 as a candidate location
for the gene underlying this disorder.
KS (MIM 244400) is recognized on the basis of a
classic triad of symptoms: situs inversus (complete mir-
ror-image reversal of left-right asymmetry of the chest
and abdominal organs [MIM 270100]), bronchiectasis,
and chronic sinusitis (Afzelius 1976; Schidlow 1994;
Afzelius and Mossberg 1995). In families with a KS pro-
band, approximately half of the proband’s affected sib-
lings display the full triad of symptoms, whereas the
other affected sibs exhibit only bronchiectasis and
chronic sinusitis but have normal left-right organ asym-
metry. KS is clinically considered a subgroup of primary
ciliary dyskinesia (PCD), formerly known as “immotile
cilia syndrome” (ICS [MIM 242650]). However, it is
unclear whether KS has the same genetic etiology as PCD
without situs inversus. These disorders are characterized
by dysmotility or immotility of the cilia in airway epi-
thelial cells, spermatozoa, and other ciliated cells of the
body. Clinical consequences of PCD cover a wide spec-
trum of symptoms mainly involving both lower and up-
per airways and the male reproductive system. Ciliary
immotility is caused by various ultrastructural defects of
cilia, with major or subtle anomalies detectable, by elec-
tron microscopy, in all or nearly all patients (Teknos et
al. 1997). The structural defects are predominantly a
total or partial absence of dynein arms (70%–80% of
cases), defects of radial spokes, nexin links, and general
axonemal disorganization with microtubular transpo-
sition (Afzelius and Mossberg 1995).
Estimates of the incidence of PCD are in the range
1/16,000–1/60,000 live births, with KS accounting for
approximately half (1/32,000–1/120,000 live births) of
these (Afzelius and Mossberg 1995). Inheritance in most
cases is autosomal recessive, although some examples of
dominant or X-linked modes of inheritance have been
reported (Narayan et al. 1994b). Nearly 200 different
polypeptides have been identified within the ciliary ax-
oneme of lower organisms; at least the same number of
proteins can be expected in axonemes of humans (Luck
et al. 1982). Mutations within many of these 200 genes
coding for ciliary proteins might cause the same or sim-
ilar pathologic consequences of ciliary dysfunction.
However, as noted in OMIM (MIM 242650), if this were
true, then we might expect that the incidence of PCD
would be much higher than that which actually occurs.
It is possible that mutations in many of these genes might
be lethal—and thus not be found among viable off-
spring. Alternatively, there may be functional redun-
dancy of some proteins, such that loss of one gene’s
product may be compensated by other proteins and thus
occur without ciliary dysfunction.
Support for PCD genes potentially located on chro-
mosome 7 is provided by several observations. First,
7q33-q34 is syntenic to a fragment of murine chromo-
some containing the hop mutation (previously named
“hpy”)—mice homozygous for this mutation have a dy-
nein defect in cilia and flagella that is similar to that
seen in some cases of PCD (i.e., dynein arms are missing
from A-tubules of the outer doublets) (Handel 1985).
Second, the gene for the b heavy chain of the outer
dynein arm maps to 7p15 region (Kastury et al. 1997),
and additional genes containing sequences highly ho-
mologous to the dynein-gene family map to 7q21-q22
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Figure 1 Multipoint LOD scores for KS families and CDO families, for chromosome 7, under the assumptions of recessive inheritance
and locus homogeneity.
(GenBank accession number AC002452) and to 7p21
(GenBank accession number AC004002). Third, there
is the case of chromosome 7 uniparental disomy and
other chromosomal anomalies with KS-like symptoms,
summarized in the letter by Pan et al. (1998). PCD can-
didates on other chromosomes include the following: (1)
the HLA region of chromosome 6p, containing the b-
tubulin gene (TUBB) (Volz et al. 1994), although limited
data reported elsewhere (Gasparini et al. 1994) did not
support the motylin gene (MLN), also residing in this
region, as being a candidate for involvement in PCD
etiology; (2) chromosome 14q32, containing the
gene for echinoderm microtubule–associated protein
(EMAP), a candidate for Usher syndrome type 1A (the
USH1A gene) (these patients exhibit, in the axonemes
of their respiratory cilia ultrastructural defects similar to
those in PCD) (Bonneau et al. 1993; Eudy et al. 1997);
(3) the dynein heavy-chain gene located on 14qter (Na-
rayan et al. 1994a); and (4) numerous other dynein,
nexin, and other microtubule-related genes rapidly ac-
cumulating in the genomics databases. Many genes have
been implicated recently in the control of the left-right
asymmetry of body development such as that observed
in KS (Overbeek 1997; Srivastava 1997; Wood 1997;
Levin and Mercola 1998). However, with the exception
of the dynein defect associated with the iv mouse mutant
(Supp et al. 1997), homologous to the human heavy-
chain dynein gene located on chromosome 14 qter, none
of these are associated with ciliary dysfunction.
We performed linkage analyses using microsatellite
markers spanning chromosome 7 in 30 PCD families
recruited in Poland. Each family had at least one member
diagnosed with PCD, and no other anomalies or dys-
morphologies were present. For linkage analyses, fam-
ilies were further classified either as KS families, if at
least one affected member was diagnosed as having KS
(i.e., as exhibiting situs inversus), or as ciliary dysfunc-
tion only (CDO) families, if none of the affected mem-
bers had situs inversus. Our sample comprised 23 KS
families with 25 KS-affected individuals and 7 CDO-
affected individuals and 7 CDO families with 9 CDO-
affected individuals. Data from all of these families were
consistent with autosomal recessive transmission (i.e.,
there were no nonsibling affected relatives). Among the
KS families, there were four pairs of affected siblings
and two trios of affected siblings; among the CDO fam-
ilies, there were two pairs of affected siblings. Two ad-
ditional KS families were ascertained as having the dis-
ease in multiple generations, consistent with a dominant
mode of inheritance, but, to date, we have been unable
to recruit a sufficient number of members to make these
families informative for linkage analysis. We chose to
analyze the KS and CDO families separately because of
the possibility that different molecular (hereditary) pa-
thologies might underlie these forms of PCD; for ex-
ample, the hop mouse mutation exhibits CDO (without
situs inversus).
Seventeen microsatellite markers spanning chromo-
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Table 2












LOD SCORE.00001 .01000 .05000 .10000
D7S531 5.28 21.942 21.008 2.379 2.139 .03100 1.00
D7S517 7.44 24.170 22.188 2.934 2.450 2.00035 .05
D7S513 17.74 .833 .812 .723 .607 .83300 1.00
D7S507 28.74 21.760 2.780 2.192 .005 .09500 1.00
D7S493 34.69 .893 .876 .801 .695 .89200 1.00
D7S629 37.51 .762 .728 .598 .455 .76200 1.00
D7S484 53.50 21.398 2.496 .021 .152 .15800 1.00
D7S519 69.03 22.117 21.119 2.470 2.213 .01030 .85
D7S502 78.65 21.750 2.745 2.092 .138 .21900 1.00
D7S669 90.42 26.693 23.680 21.790 21.029 2.00567 .05
D7S657 104.86 24.870 22.738 21.429 2.875 2.00680 .05
D7S527 108.59 22.540 21.526 2.819 2.496 2.00308 .05
D7S486 124.08 24.700 22.453 21.149 2.627 2.00311 .05
D7S530 134.55 24.470 22.479 21.192 2.666 2.00335 .05
D7S640 137.83 27.445 24.200 22.217 21.368 2.01008 .05
D7S684 147.22 24.761 22.748 21.394 2.812 2.00497 .05
D7S550 178.41 24.643 22.404 21.124 2.619 2.00333 .05
some 7, with average interval of 10.8 cM, were analyzed
by fluorescence-based, semiautomated DNA-sizing tech-
nology (Ziegle et al. 1992) using Applied Biosystems 373
Automated DNA Sequencers and GENESCAN and
GENOTYPER software (Applied Biosystems/Perkin-El-
mer). Pairwise LOD-score analyses were performed by
means of the FASTLINK program (Scha¨ffer 1996). LOD
scores allowing for locus heterogeneity (Ott 1991) were
calculated by means of a program developed for this
purpose (S. R. Diehl, unpublished data). Our unpub-
lished program performs the same simple admixture cal-
culation as is performed by publicly available programs
such as HOMOG (and provides identical results in nu-
merous benchmark comparisons), and it is used for data-
formatting convenience only. A copy of our program is
available on request from the corresponding author.
Multipoint LOD scores for all of chromosome 7 were
calculated by means of the GENEHUNTER program
(Kruglyak et al. 1996) and the sex-average map distances
reported by the Marshfield Medical Research Founda-
tion. For all LOD-score analyses, we assumed a recessive
mode of inheritance, 50% penetrance for homozygous-
mutant genotypes, 0.000013% penetrance for wild-type
and heterozygous genotypes (i.e., PCD phenocopies),
and PCD disease-allele frequency of .00514. These as-
sumptions yield a population prevalence consistent with
that reported for PCD.
Pairwise and multipoint LOD scores for the KS fam-
ilies are shown in table 1 and figure 1, respectively. The
last column in the table (“Alpha at Maximum LOD
Score”) refers to the estimated proportion of families in
which there is linkage to the marker under locus het-
erogeneity (i.e., the maximum LOD score obtained by
varying both the recombination fraction and the pro-
portion of families linked). Pairwise LOD scores under
locus homogeneity for 17 microsatellite markers of chro-
mosome 7 are all negative and range between 21.096
and 213.868, at a recombination fraction (v) of .00001,
providing no support for linkage. Even if we allow for
locus heterogeneity within the KS families (i.e., some KS
families have linkage to a gene on chromosome 7,
whereas others do not), the maximum pairwise LOD
score obtained for any of the 17 markers is only 0.52.
Multipoint LOD scores under the assumption of ho-
mogeneity exclude (at LOD ! 22.0) a KS-susceptibility
locus from most of chromosome 7 (fig. 1). The only part
of the chromosome not formally excluded is the region
between the last two markers on the chromosome, where
a gap of 131 cM exists, and even this region is not
positive but only lacks power for exclusion. If we allow
for locus heterogeneity, the highest multipoint LOD
score for the entire chromosome is still only 0.27, which
could easily be due to chance. By contrast, pairwise and
multipoint LOD scores for the CDO families, shown in
table 2 and figure 1, respectively, provide at least a weak
suggestion of possible linkage to chromosome 7. We note
that, interestingly, the highest multipoint LOD scores for
the CDO families, 1.41, occurs at precisely the position
on chromosome 7p15 where the gene for the b heavy
chain of the outer dynein arm is located (Kastury et al.
1997). The same maximum LOD score is obtained when
we allow for locus heterogeneity within the CDO fam-
ilies, since all families provide evidence of linkage to this
region (i.e., no evidence of recombination with markers
D7S493 or D7S629; see table 2). Analyses of combined
KS and CDO families provide no significant evidence of
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linkage, with a maximum multipoint LOD score, cal-
culated by the GENEHUNTER program, of only 0.56
for the entire chromosome, occurring at the same lo-
cation where the highest LOD score (1.41) for the CDO
families occurs.
Since our linkage results exclude chromosome 7 as a
candidate location for a KS gene, the cytogenetic evi-
dence suggested that this region should be reevaluated.
Ciliary structural anomalies are always or almost always
found in cases of KS (Teknos et al. 1997); however, de-
spite the absence of normal ciliary motion, no visible
ciliary ultrastructural defects were found in the patient
with situs inversus and paternal isodisomy of chromo-
some 7 who was reported by Pan et al. (1998). It is
possible that the situs inversus of this patient was caused
by a gene solely involved in heterotaxy but without any
ciliary ultrastructural anomaly (Overbeek 1997; Srivas-
tava 1997; Wood 1997; Levin and Mercola 1998). Two
other studies have reported cytogenetic anomalies of
chromosome 7 that are associated with laterality defects
(Genuardi et al. 1993; Koiffman et al. 1993). Further-
more, the lack of normal ciliary motion without ciliary
structural anomalies, as was observed in Pan et al.’s
patient, may represent a secondary effect of cytolysis and
cell destruction of bronchial epithelial cells in CF
(Cheung and Jahn 1976), although this finding remains
controversial (Rutland et al. 1983). Alternative expla-
nations include involvement of genes involving ciliary
function (in addition to a gene causing situs inversus).
Such a ciliary-function gene might also be located on
chromosome 7, or, coincidentally, the patient studied by
Pan and colleagues might have a mutation in a gene
influencing ciliary function and located elsewhere in the
genome. Our suggestive LOD score of 1.41 at the chro-
mosomal location of a dynein gene in the CDO families
that we have studied is consistent with the involvement
of a ciliary-function gene on chromosome 7, but the
ultimate resolution of these issues will require additional
data. Although this LOD score is quite small, it may be
especially noteworthy in view of the fact that the limited
number of CDO families available can produce a max-
imum LOD score of only 1.49, even under complete
linkage and full marker informativeness, as we have de-
termined by means of the SLINK program (Weeks et al.
1990). The KS families, by contrast, can yield LOD
scores as high as 3.95, under complete linkage and com-
plete informativeness.
We conclude from our data presented here that the
gene(s) responsible for KS is (are) not likely to be located
on chromosome 7. Our suggestion of possible linkage
for the CDO families should be taken with caution, be-
cause of the small size of the sample analyzed; however,
especially because the b heavy chain of the outer dynein
arm maps to the same location as our positive LOD score
of 1.41, we suggest that this region should be considered
a high-priority location for follow-up linkage studies in
additional CDO families.
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A New Locus for Nonsyndromic Hereditary Hearing
Impairment, DFNA17, Maps to Chromosome 22 and
Represents a Gene for Cochleosaccular Degeneration
To the Editor:
Over the past several decades, the proportion of the
population with hearing impairment attributed to ge-
netic factors has increased as modern medicine has be-
come both more adept at controlling maternal and
pediatric infections and better educated about the
iatrogenic causes of hearing impairment. At present, as
much as one-half of all congenital hearing impairment
is considered to have an underlying genetic component
(Arnos et al. 1992; Brookhouser 1994; Cohen and Gor-
lin 1995; Fraser 1995), making hereditary hearing im-
pairment (HHI) one of the most common inherited hu-
man deficits.
Cochleosaccular degeneration (CSD) is the most com-
mon histopathologic finding in cases of profound con-
genital HHI. It is estimated to occur in ∼70% of cases
(Ormerod 1960; Bergstrom 1980; Gulya and Juhlin
1992). CSD was described first by Scheibe in 1892 and
is more commonly known as “Scheibe dysplasia.” It af-
fects structures that are derived from the pars inferior
of the otocyst. Thus, the membranous cochlea and sac-
cule are affected, but the osseous labyrinth, the mem-
branous utricle, and the semicircular canals are normal.
Because there is no clinically available test to diagnose
CSD, postmortem histologic examination of the tem-
poral bone is required. The histopathology of CSD is
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characterized by a loss of neurosensory hair cells and
their supporting cells in the cochleae and sacculae. Coch-
lear and vestibular nerve atrophy varies and ranges from
none to severe. Reissner’s membrane and the saccu-
lar wall are typically collapsed. The stria vascularis
is atrophic with inclusion of abnormal periodic acid-
Schiff–positive material. The pathology in the cochlea is
typically most severe in the basal turn, with progressive
preservation of normal architecture toward the apex.
Occasionally, endolymphatic hydrops is present, indi-
cating a disturbance in ionic and osmotic regulation.
Although CSD is relatively common, its molecular
pathogenesis remains to be deciphered. Genetic analysis
of families with HHI associated with CSD represents a
potential route toward identification of genes responsi-
ble for intact and functional membranous structures
within the cochlea. First, histopathology offers physical
evidence of the specific tissues that the disease gene af-
fects. Second, it may provide clues to the functions of
the mutant gene. Finally, animals with similar histopa-
thology serve as excellent models for CSD-associated
hearing impairment. Previously, no nonsyndromic HHI
loci had been associated with CSD, and, with the ex-
ception of the DFNA9 locus, there were no nonsyn-
dromic HHI loci that had been both genetically mapped
and histologically characterized (Manolis et al. 1996).
Here we present the first reported mapping of a gene
responsible for CSD. The family transmitting this mu-
tant gene is a previously described, multigenerational,
nonconsanguineous American family with autosomal
dominant HHI (Lalwani et al. 1997).
The family studied was identified through the tem-
poral-bone database at the House Ear Institute in Los
Angeles. Institutional-review-board approval was ob-
tained for the human-research protocols from the House
Ear Institute and the National Institute on Deafness and
from Other Communication Disorders at the National
Institutes of Health. Eighteen members of the family
were enrolled in the study, of whom eight are affected.
Extensive medical histories were obtained, and audiolog-
ical evaluations were performed as described elsewhere
(Lalwani et al. 1997). In addition, temporal bones and
the brain stem, removed at autopsy from the proband,
were analyzed as described elsewhere (Lalwani et al.
1997).
The family has been described in detail previously
(Lalwani et al. 1997). In summary, the affected family
members exhibit nonsyndromic HHI with an autosomal
dominant mode of transmission; there was no pigmen-
tary abnormality in any of the affected individuals. Ini-
tially, the hearing impairment would begin at age 10
years and would involve only the high frequencies; by
the 3d decade of life, affected family members had mod-
erate to severe deafness. Histologic examination of the
proband’s temporal bone exhibited classic CSD, with
degeneration of the organ of Corti, the saccular epithe-
lium, and the stria vascularis. In addition, there was
asymptomatic loss of neurons and gliosis in the inferior
olivary nucleus.
Genomic DNA was extracted from whole blood by
standard phenol extraction. Samples were quantified by
spectrophotometry and were diluted to 25 ng/ml, for am-
plification by PCR. A 10-cM genome scan was produced
with the ABI Prism Linkage Mapping Set, version 1.0
(PE Applied Biosystems), consisting of fluorescently la-
beled markers detecting microsatellite polymorphisms
(Weber and May 1989; Reed et al. 1994). Fine mapping
was accomplished with fluorescently labeled MapPairs
from Research Genetics.
PCR used 50 ng of genomic DNA in a 10-ml reaction.
The final reaction consisted of 1# PCR Perkin-Elmer
buffer; 2 pmol of fluorescently labeled forward primer;
2 pmol of reverse primer; 50 mM each of dCTP, dGTP,
dTTP, and dATP; 2.0 mM MgCl2; and 0.25 U of
AmpliTaq Gold DNA Polymerase (PE Applied Biosys-
tems). Reactions were started, at 957C for 12 min, to
activate the polymerase. Thirty-four cycles of amplifi-
cation were completed in the following protocol: 947C
for 45 s, 577C for 45 s, and 727C for 60 s. Samples were
maintained at 727C for 10 min, for extension. Products
were resolved on 4.25% denaturing polyacrylamide gels
(6 M urea) and were visualized on a 377 prism (PE
Applied Biosystems).
The FASTLINK program package enabled calculation
of two-point and multipoint LOD scores over the entire
genome (Cottingham et al. 1993; Scha¨ffer et al. 1994).
A dominant mode of inheritance with complete pene-
trance was assumed. A phenocopy rate of 0.1% was
assumed, since this is the incidence of congenital hearing
impairment in the United States. The phenotype of in-
dividuals !10 years old (V:1 and V:3 are 4 and 8 years
old, respectively) was assumed to be unknown, since
hearing loss begins at this age in this family.
Previous SIMLINK analysis had shown that the family
could generate a maximum LOD score of 4.033, with
a mean 5 SD of (Boehnke 1986; Lal-2.872 5 0.036
wani et al. 1997). Genomic scanning at 10-cM intervals
identified on chromosome 22 a region with a LOD score
13.0 and exclusion of the remainder of the genome; fine
mapping of the region by means of eight additional
markers in the linked region was performed. A maxi-
mum LOD score of 3.98 was obtained at D22S283 (table
1). Haplotypes were then constructed to determine the
critical recombination events (fig. 1). The centromeric
recombination occurs in individual IV:6, between mark-
ers D22S689 and D22S280. The telomeric recombina-
tion occurs between markers D22S282 and D22S444 in
several individuals (III-4, IV-7, IV-8, and IV-11). These
critical crossovers define a linked region spanning a
16.89–22.97-cM interval, which includes D22S280 near
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Table 1
Two-Point LOD Scores Calculated across Linkage Region, with
Relative Genetic Distances, According to the Marshfield Medical
Research Foundation Genetic Map
MARKER




D22S420 2` .93 .86 4.06
GCT10C10 2` 1.86 1.57 18.10
D22S315 2` 1.90 1.47 21.47
D22S689 2` 2.04 1.76 28.57
D22S280 3.22 2.55 1.84 31.30
D22S281 3.22 2.93 2.39 31.84
D22S691 2.87 2.26 1.59 32.39
D22S685 2.16 1.72 1.26 32.39
D22S683 3.53 2.81 2.03 36.22
D22S277 3.52 2.89 2.21 36.22
D22S283 3.98 3.26 2.49 38.62
D22S426 3.78 3.06 2.28 41.42
D22S692 1.91 1.48 1.02 41.42
IL2RB 3.30 2.94 2.39 42.81
D22S1045 3.33 2.65 1.92 42.81
D22S445 2.06 1.79 1.44 45.82
D22S423 1.14 .88 .63 46.42
D22S282 2.99 2.27 1.50 48.19
D22S444 2` 21.44 2.30 51.54
D22S274 2` 21.57 2.51 51.54
the centromere and D22S282 near the telomere. This
region corresponds to the cytogenetic bands 22q12.2-
22q13.3.
Two individuals, V:1 and V:3, who are !10 years old,
were classified as unknown and therefore did not con-
tribute to the LOD score. Individual V:1 does not carry
the disease haplotype, and her audiogram is completely
normal. Her brother, V:3, is 8 years old and currently
has a normal audiogram. However, he carries a portion
of the disease haplotype. If he does become affected
as he ages, the linked region will be defined by flank-
ing markers D22S689 and D22S423, encompassing a
14.52–17.85-cM region. On the other hand, if he re-
mains unaffected, the linked region will be narrowed
to 1.77–5.72 cM, flanked by markers D22S445 and
D22S444.
Remarkable progress has been made in the identifi-
cation of genes responsible for nonsyndromic HHI. To
date, the locations of 18 autosomal dominant, 20 au-
tosomal recessive, and 8 X-linked hearing-loss genes
have been identified (Hereditary Hearing Loss). Here,
we report identification of DFNA17, a new locus for
autosomal dominant nonsyndromic HHI, on chromo-
some 22q12.2-q13.3. Typically, autosomal dominant
HHI is characterized by postlingual onset of hearing loss,
in contrast to the prelingual onset of deafness observed
in autosomal recessive cases. DFNA17 is characterized
by high-frequency hearing loss that begins at age 10
years, progresses to severe deafness by the 3d decade,
and involves all frequencies. This auditory phenotype is
also shared by other previously mapped autosomal dom-
inant nonsyndromic loci, including DFNA2, DFNA5,
DFNA7, and DFNA9. High-frequency hearing loss that
progresses to involve all frequencies is typical of pres-
bycusis, or hearing loss associated with aging. Consid-
ered the most common form of hearing impairment, age-
associated hearing impairment is thought to have a
multifactorial etiology, with heredity being an important
contributing factor. Therefore, the gene responsible for
DFNA17, as well as other nonsyndromic HHI genes
associated with progressive hearing loss, may provide
critical insights into an understanding of the molecular
pathophysiology of presbycusis.
The genes responsible for hearing impairment, at
seven of the autosomal dominant nonsyndromic HHI
loci, have been identified during the past 2 years (Lal-
wani and Castelein 1999). Mutations in an unconven-
tional myosin gene, myosin VIIA, have been demon-
strated to be responsible for DFNA11 (Liu et al. 1997).
In the same year, mutations in the diaphanous gene were
shown to be the pathogenic cause of DFNA1 (Lynch et
al. 1997). In the first 6 mo of 1998, mutations in con-
nexin 26, TECTA, and POU4F3 were found to be re-
sponsible for DFNA3, DFNA8/12, and DFNA15, re-
spectively (Denoyelle et al. 1998; Vahava et al. 1998;
Verhoeven et al. 1998). These genes have a wide variety
of functions, including intercellular communication via
gap-junction formation by connexin 26, regulation of
actin polymerization by diaphanous-gene, transcription
regulation by POU4F3, tectorial membrane constitution
by TECTA, and, finally, anchoring of the actin cytoskele-
ton by myosin VIIA. The wide range of functions sub-
served by the DFNA genes reflects the heterogeneity of
genes involved in nonsyndromic deafness (DFN).
Although the pace of the mapping and identification
of mutated genes that cause nonsyndromic HHI has been
rapid, their biologic role in the determination of cochlear
structure and function is largely unknown. The absence
of temporal-bone histologic data from families that have
been used for mapping studies has hindered our under-
standing of the effects of the mutant hearing genes. The
DFNA17 family was identified by histologic examina-
tion of the temporal bone of the proband, unlike most
families with HHI, who are identified initially by clinical
symptoms. Hearing impairment in the DFNA17 family
is associated with CSD, considered to be the most com-
mon cause of profound congenital hearing impairment,
accounting for 70% of cases with HHI. DFNA17 rep-
resents the first nonsyndromic gene for CSD. However,
CSD is likely genetically heterogeneous, because a va-
riety of clinical forms of HHI can lead to the common
histopathologic manifestation. DFNA9 is the only other
DFN locus for which the human temporal-bone histo-
pathology has been reported. Affected individuals in this
Figure 1 Haplotypes of chromosome 22. Haplotypes for individual III:2, the proband, are inferred from the haplotypes of his children
and wife. The disease haplotypes are boxed.
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family exhibit mucopolysaccharide depositions in the
neural channels of the inner ear (Khetarpal et al. 1991;
Khetarpal 1993), and the gene for hearing impairment
in this family maps to 14q12-13 (Manolis et al. 1996).
DFNA17 maps to a relatively large genetic region of
16.89–22.97 cM, which is typical for mapping studies
that comprise families similar in size to the DFNA17
family. Unfortunately, this region is too large for posi-
tional cloning. Alternative approaches to identification
of the mutated gene include investigation of cloned genes
in the linked region and investigation of mouse models
of deafness mapped to syntenic regions. There are many
expressed sequence tags and genes that have been
mapped to 22q12.2-13.3 and that thus represent poten-
tial candidate genes for DFNA17 (Science/The Human
Gene Map). The history of the search for hearing-im-
pairment genes has demonstrated that it is difficult to
predict a candidate gene on the basis of its known or
putative function (e.g., PDS, a putative sulfate-trans-
porter gene, has been found to be associated with hear-
ing impairment). Therefore, it is difficult to select, for
mutation analysis, a candidate gene expressed in the
DFNA17 region.
A sample of the genes expressed in the linked region
includes those for metalloproteinase inhibitor 3 precur-
sors, sodium/glucose cotransporter 1, a-N-acetylgalac-
tosaminidase precursor, platelet-derived growth factor,
and nonmuscle myosin heavy-chain A (NMMHC-A).
Because mutations in two myosin genes are known to
cause hearing impairment (Liu et al. 1997; Wang et al.
1998), this class of genes deserves particular attention
as potential candidates. Thus the nonmuscle myosin
within the linked region represents a strong candidate
for DFNA17 (Saez et al. 1990; Simons et al. 1991;
Toothaker et al. 1991). Human NMMHC-A is a class
II conventional myosin, unlike unconventional myosins
VIIA and 15, which have been shown to cause hearing
impairment. However, NMMHC-A is not a traditional
striated-muscle-cell myosin, since it is expressed in the
rat intestine, testis, liver, lung, thymus, kidney, and heart
and not in striated muscle (Simons et al. 1991). Recently
it has been shown that NMMHC-A is also expressed in
the cochlea (authors’ unpublished data).
Another approach toward identification of the
DFNA17 gene is to use mouse models of deafness that
map to the syntenic region in the mouse. Human myosin
VIIA and myosin 15 have been identified by initial char-
acterization of the homologous mouse models (Liu et al.
1997; Wang et al. 1998). The mouse syntenic region for
DFNA17 includes chromosomes 11 and 15. No mouse
deafness models have yet been reported that map to a
region syntenic with the human DFNA17. One mouse
deafness model—dominant spotting, or kit—displays
histology that resembles that of human CSD (Bock and
Steel 1983; Steel and Bock 1983), but the gene for this
mouse phenotype maps to the homologous region of
human chromosome 4. Other animal models for CSD
include Dalmatian dogs, Hedlund white mink, and the
deaf white cat (Mair 1973; Steel and Bock 1983). How-
ever, none of these loci have been mapped, because of
the unavailability of genetic markers for these species.
Furthermore, unlike the family in the present study, these
animal models of CSD are associated with skin-pigment
abnormalities due to a lack of melanocytes.
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Two Novel Single–Base-Pair Substitutions Adjacent to
the CAG Repeat in the Huntington Disease Gene
(IT15): Implications for Diagnostic Testing
To the Editor:
The CAG-expansion mutation that causes Huntington
disease (HD) was first identified in 1993 (Huntington’s
Disease Collaborative Research Group 1993). The stan-
dard PCR assay used by clinical laboratories to deter-
mine repeat length amplifies only the CAG repeat
(Andrew et al. 1994; The ACMG/ASHG Huntington
Disease Genetic Testing Working Group 1998). The ad-
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Figure 1 A, Repeat region of the HD gene (GenBank accession
number L12392, base pairs 316–585) and primers used for amplifi-
cation of the CAG repeat (HD1 and HD3-3′), the CCG repeat (HD3-
5′ and HD2), and the combined CAG/CCG repeat (HD1 and HD2).
For the CAG-only protocol, 500 ng genomic DNA was incubated at
997C for 3 min; 400 nM each of primer HD1 and fluorescently tagged
primer HD3-3′, 2.5 U Taq polymerase, and buffer containing 50 mM
Tris-HCl (pH 8.3), 50 mM KCL, 200 mM each dNTP, 1.5 mM MgCl2,
and 8# MasterAmp PCR enhancer (Epicenter Technologies) were
added, followed by denaturation at 957C for 5 min; 33 cycles of 957C
for 45 s, 677C for 45 s, and 727C for 1 min; and an extension at 727C
for 7 min. The CCG-only protocol was as described above, except
that annealing was at 607C and the buffer contained 50 mM KCl, 10
mM Tris-HCl (pH 8.3), 1 mM MgCl2, .01% gelatin, 10% dimethyl
sulfoxide, 1.5 U Taq polymerase, 100 mM dGTP, 100 mM deaza-dGTP,
and 200 mM each of dATP, dTTP, and dCTP. The CAG1CCG protocol
was as described elsewhere (Huntington’s Disease Collaborative Re-
search Group 1993; Stine et al. 1993), modified for automated fluo-
rescent analysis. All assays are 51 triplet. B, Three substitutions iden-
tified in the repeat region of the HD gene.
jacent CCG repeat varies in length by 7–12 triplets (An-
drew et al. 1994), and the CCT repeat following the
CCG repeat can be either two (common) or three (rare)
triplets in length (Pecheux et al. 1995). A PCR assay
that amplifies across all three repeats (referred to as the
“CAG1CCG assay”), taking advantage of the common
CCG repeat–length polymorphism, remains valuable for
the detection of a second allele in cases in which only a
single allele is detected by the CAG-only method (Gold-
berg et al. 1993; The ACMG/ASHG Huntington Disease
Genetic Testing Working Group 1998). By use of a third
assay, which determines the combined length of the CCG
and CCT repeats (referred to as the “CCG-only assay”;
Andrew et al. 1994), CAG-repeat length can be calcu-
lated. Previously, an apparently rare mutation was iden-
tified, in which the CAA triplet immediately following
the CAG repeat is absent, leading to failure of the stan-
dard PCR assay for repeat length (Gellera et al. 1996).
We now report two additional single-base substitutions
that can lead to assay failure or errors in the calculation
of CAG-repeat length.
In the first case, a 51-year-old man with a 14-year
history of a progressive syndrome typical of HD was
referred for testing for the HD expansion mutation. His
father had died, at age 56 years, of a myocardial in-
farction, and an extensive review of the pedigree revealed
no affected relatives. After informed consent was ob-
tained, DNA was extracted from blood (Gentra). The
CAG-only assay (fig. 1A) yielded a single peak, indicat-
ing a CAG-repeat length of 19 triplets. The CCG-only
assay (fig. 1A) generated two peaks, indicating the pres-
ence of alleles containing 7 and 10 CCG triplets. The
CAG1CCG assay yielded a single peak consistent with
a CAG-repeat length of 19 or 20 triplets. A new 5′ primer
was synthesized that was identical to HD1, except for
the absence of the 3′ terminal C. By use of this primer
and primer HD2, the normal length CAG repeat of 20
triplets and an expanded repeat of 41 triplets were
detected.
To establish the reason for the failure of the original
HD1 primer to amplify the expanded repeat, genomic
DNA was reamplified by use of primers HD7-5′ (5′-
GGACGGCCGCTAGGTTC-3′) and HD7-3′ (5′-CGG-
CTGAGGAAGCTGAGGAGG-3′) and a PCR protocol
similar to the original CAG-only assay. PCR products
were cloned into pCRII (Invitrogen), and sequence was
obtained from three independent clones containing the
expanded allele. Each clone had an expanded CAG re-
peat of 41 triplets, as predicted by the assay with the
shortened HD1 primer, that was adjacent to a CCG re-
peat of 7 triplets. The sequence also revealed the presence
of a CrG substitution of the base immediately preceding
the CAG repeat (fig. 1B).
In the second case, an unaffected spouse of a patient
with HD was tested for HD repeat lengths, after in-
formed consent was obtained, as part of a presympto-
matic testing protocol for her child. The CAG repeats
determined by the CAG-only assay were 17 and 28 trip-
lets in length. The CCG-only assay yielded a single peak,
suggesting two CCG alleles of seven triplets each. The
CAG1CCG assay indicated the presence of an allele of
(CAG)17, as expected, and a second allele of (CAG)30,
two triplets longer than was predicted by the other as-
says. To account for this discrepancy, genomic DNA was
amplified, and the products were cloned into pCRII, as
described above. Interpretable sequences were obtained
from 11 clones. Eight clones contained a normal allele
with, as expected, 7 CCG triplets and either 16 (three
clones) or 17 (five clones) CAG triplets. Three clones
contained a second allele with either 26 (one clone) or
27 (two clones) CAG triplets. In all three of these clones,
the CCG repeat consisted of 12 consecutive CCG triplets
without the CCA triplet that normally precedes the CCG
repeat (fig. 1B).
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The sequence of the regions adjacent to the CAG re-
peat provides an explanation for the PCR results in these
two cases. In the first case, the CrG substitution falls
precisely at the 3′ terminal base of the HD1 PCR primer,
apparently preventing efficient annealing of this primer
and, hence, synthesis of a product. The substitution re-
sults in a change from phenylalanine to leucine in the
encoded protein. The clinical phenotype of the first case
is typical of HD, and this substitution of one neutral
hydrophobic amino acid for another possibly has no
consequences on phenotype. Among the 1,236 subjects
that we have tested for HD repeat length, this is the only
case for which the HD1 primer has failed consistently,
suggesting that this CrG substitution is a rare mutation.
The ArG polymorphism in the second case is silent,
because both codons encode proline. The absence of the
CCA codon in the second case presumably led to the
misannealing of primer HD3-5′, which caused the false
finding of a CCG repeat of seven triplets. In 26 other
subjects tested with all three assays (CAG-only, CCG-
only, and CAG1CCG), we did not detect a repeat-length
discrepancy of two triplets, suggesting that absence of
the CCA repeat is a relatively uncommon variant. The
actual (CCG)12 repeat probably indicates the common
(CCG)10 variant coupled with an ArG substitution that
converts the adjacent CCACCG sequence into CCG-
CCG. However, other combinations of deletions and in-
sertions also could have resulted in this change. The
variation in length among the cloned PCR products of
the HD region of the second case may reflect either re-
peat-length instability during plasmid replication in bac-
teria or somatic variation of the repeat in leukocytes
from the subject.
These two variants have implications for the deter-
mination of the repeat length in the HD gene. The first
case demonstrates that test results indicative of CAG
repeat–length homozygosity may be incorrect, particu-
larly if the standard primer, HD1, is used. For cases in
which both the CAG-only and the CAG1CCG assays
detect a single repeat, a reasonable next step would be
to repeat the assays, with the HD1-short primer. If this
assay or other PCR assays using alternative primers fail
to reveal a second allele, then a search, by Southern blot
analysis, for an expanded allele would be prudent. Sim-
ilarly, the second case suggests the use of an alternative
primer in those cases for which CCG-repeat length is
important but for which the standard assays of repeat
length yield discrepant results. More broadly, these cases
illustrate the pitfalls inherent in PCR-based assays of
genetic mutations.
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The Interpretation of the Parameters in the
Transmission/Disequilibrium Test
To the Editor:
The transmission/disequilibrium test (TDT) proposed by
Spielman et al. (1993) is a valid test for linkage in struc-
tured populations, irrespective of whether the families
are simplex, multiplex, or multigenerational (Spielman
and Ewens 1996). Its power to detect linkage of complex
traits is potentially greater than that of allele-sharing
methods (Risch and Merikangas 1996). The origi-
nal TDT has been extended by a number of groups—
including Sham and Curtis (1995), Schaid (1996), and
Spielman and Ewens (1996)—to the study of multiallelic
markers. Assuming Hardy-Weinberg equilibrium for the
population under study, I present relationships between
parameters in the TDT and the disease susceptibility car-
ried by marker alleles. I hope that these relationships
make the interpretation of the observed transmission dis-
equilibrium more intuitive and that they yield further
insight into the TDT.
Consider a marker H with n alleles, H1,)Hn, having
allele frequencies h1,)hn. Assume that the disease gene
D has two alleles, D1 and D2, with allele frequencies p1
and , respectively, and that the penetrancep 5 1 2 p2 1
for genotype DuDv is fuv, where or 2. Further-u, v 5 1
more, denote the recombination fraction between H and
D as v and measure the set of linkage-disequilibrium
values, between these two loci, in terms of d 5H Di u
, where and or 2. First,P(H D ) 2 h p i 5 1, ) ,n u 5 1i u i u
consider the transmission of a marker allele from one
parent to the affected offspring. Let (a parent hasP 5 Pij
genotype HiHj and transmits HiFoffspring is affected).
Sethuraman (1997) has shown that, if a sample of af-
fected children together with their parents are ascer-
tained at random from a population in Hardy-Weinberg
equilibrium, then
P 5 (p f 1 p f )[h P(H D )ij 1 11 2 12 j i 1
2v(h d 2 h d )]/Kj H D i H Di 1 j 1
1(p f 1 p f )[h P(H D )1 12 2 22 j i 2
2v(h d 2 h d )]/K ,j H D i H Di 2 j 2
P 5 (p f 1 p f )[h P(H D )ji 1 11 2 12 i j 1
2v(h d 2 h d )]/Ki H D j H Dj 1 i 1
1(p f 1 p f )[h P(H D )1 12 2 22 i j 2
2v(h d 2 h d )]/K ,i H D j H Dj 2 i 2
where is the disease preva-2 2K 5 p f 1 2p p f 1 p f1 11 1 2 12 2 22
lence in the population. Sham and Curtis (1995) ex-
pressed the Pij in different but equivalent forms. In the
following discussion, assume that , since, betweenv 5 0
loci having linkage disequilibrium, v is generally very
close to 0. When ,v 5 0
P 5 h [(p f 1 p f )P(H D )ij j 1 11 2 12 i 1
1(p f 1 p f )P(H D )]/K ,1 12 2 22 i 2
P 5 h [(p f 1 p f )P(H D )ji i 1 11 2 12 j 1
1(p f 1 p f )P(H D )]/K . (1)1 12 2 22 j 2
Let (an individual is affected F thisP(affectedFH ) 5 Pi
individual receives allele Hi from one parent). This con-
ditional probability can be regarded as the genetic risk
that allele Hi carries for the disease susceptibility. The
value of P(affected F Hi) can be calculated as follows:
P(an individual is affectedd this individual
receives H from one parent)i
5 P(an individual receives H from onei
parent and is affected)/P(H )i
2 2
5 P(an individual receives H D fromOO i u
u51 51v
one parent, receives D from the otherv
parent, and is affected) /hi
2 2
5 P(an individual receives H D fromOO i u
u51 51v
one parent and receives D from the otherv
parent)P(affected d genotype D D )/hu iv
2 2
5 P(H D )P(D )f /h .OO i u u iv v
u51 51v
The last equation follows from the assumption of Hardy-
Weinberg equilibrium. Thus,
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P(affectedFH ) 5 [(p f 1 p f )P(H D )i 1 11 2 12 i 1
1(p f 1 p f )P(H D )]/h ,1 12 2 22 i 2 i
P(affectedFH ) 5 [(p f 1 p f )P(H D )j 1 11 2 12 j 1
1(p f 1 p f )P(H D )]/h . (2)1 12 2 22 j 2 j
From equations (1) and (2),
P 5 P(affectedFH )h h /K ,ij i i j
P 5 P(affectedFH )h h /K .ji j i j
Therefore, the following relationship relates Pij to
P(affected F Hi):
P P(affectedFH )ij i5 . (3)
P P(affectedFH )ji j
From equation (3), it can be seen that the transmis-
sion/disequilibrium ratio Pij/Pji for HiHj parents is in-
dependent of allele frequencies. For n alleles, the
transmission/disequilibrium ratios Pij/Pjin(n 2 1)/2
are determined by independent parametersn 2 1
P(affectedFHi).
Let nij denote the number of HiHj parents who trans-
mit Hi to the affected offspring. Then, conditional on
( ), nij follows the binomial distributionn 1 n i ( jij ji
P(affectedFH )iB n 1 n , .ij ji[ ]P(affectedFH ) 1 P(affectedFH )i j
This naturally leads to the logistic regression proposed
by Sham and Curtis (1995), who did not interpret the
parameters as the genetic risks carried by different
marker alleles.
Schaid (1996) studied the case when the joint trans-
mission of two parents is considered simultaneously. Let
P 5 P(one parent has genotype H Hik,jl i j
and transmits H and the otheri
parent has genotype H H and transmitsk l
H d offspring is affected) .k
Without the assumption of Hardy-Weinberg equilib-
rium, it can be shown that
P P(affectedFH H )ik,jl i k5 , (4)
P P(affectedFH H )jl,ik j l
where P(affected F HiHk) is the conditional probability
that a person having genotype HiHk is affected—that is,
the penetrance for marker genotype HiHk (Schaid 1996).
Therefore, when two parents are considered jointly,
Pik,jl/Pjl,ik is determined by the ratio of the penetrances
for genotypes HiHk and HjHl. For n alleles, there are
possible genotypes; so, a total ofn(n 1 1)/2 n(n 1
parameters are needed to quantify Pik,jl/Pjl,ik.1)/2 2 1
Schaid (1996) discussed several ways to code the gen-
otypes in the transmission/disequilibrium test.
When each parent is examined separately, the contri-
butions from the two parents are implicitly assumed to
be independent. This is true if
P(affectedFH H ) P(affectedFH ) P(affectedFH )i k i k5 ,
P(affectedFH H ) P(affectedFH ) P(affectedFH )j l j l
which holds if and only if (Knapp et al. 1993).2f 5 f f12 11 22
The relationships in equations (3) and (4) have been
used to develop transmission/disequilibrium tests for
multiple tightly linked markers (H. Zhao, K. R. Meri-
kangas, and K. K. Kidd, unpublished results). They are
also useful in the study of gene-environment interac-
tions. For simplicity, assume that an environmental
exposure R—for example, smoking—is classified as
being either present ( ) or absent ( ). LetR 5 1 R 5 0
(one parent has genotype HiHj and transmits Hi,
RP 5 Pik,jl
and the other parent has genotype HkHl and transmits
Hk F offspring is affected and environmental exposure
is R). Denote the penetrance for genotype DuDv under
environmental exposure R by means of . If genotypeRfuv
DuDv and environmental exposure R have multiplica-
tive effects on the disease susceptibility—that is, 1f 5uv
—then it can be shown that0lfuv
1 0P Pik,jl ik,jl5 .1 0P Pjl,ik jl,ik
Therefore, is independent of the environmentalR RP /Pik,jl jl,ik
exposure variable R when the genotypes and the envi-
ronmental exposure have multiplicative effects on the
disease susceptibility. To test nonmultiplicative gene-en-
vironment interactions, standard statistical tests may be
performed, to determine whether the transmission/dis-
equilibrium ratios among families having the expo-
sure—that is, —are the same as the transmis-1 1P /Pik,jl jl,ik
sion/disequilibrium ratios among families without the
exposure—that is, . However, for nonmultipli-0 0P /Pik,jl jl,ik
cative gene-environmental interactions—for example,
additive gene-environment interactions with 1f 5 d 1uv
—there is no simple relationship between and0 1 1f P /Pu ik,jl jl,ikv
.0 0P /Pik,jl jl,ik
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Cancer Genetics and Insurance
To the Editor:
Rodriguez-Bigas et al. (1998) made a commendable ef-
fort to ask 1,000 of a total of 5,178 U.S. health, dis-
ability, and life insurance companies about their policies
(and conditions) for insuring patients and asymptomatic
carriers of the gene for autosomal dominant hereditary
nonpolyposis colorectal cancer (HNPCC). The low re-
sponse rate (7.7%) and the heterogeneity of the insur-
ance companies’ attitudes (which ranged from accep-
tance to rejection of people with these types of risks) do
not warrant the authors’ optimistic conclusions that “the
majority of health, life, and disability insurance provid-
ers with an opinion would be willing to sell insurance
to both HNPCC gene carriers and at-risk individuals”
(Rodriguez-Bigas et al. 1998, p. 737). In The Nether-
lands (population 15,000,000), the health and life in-
surance companies expressed the intention to prolong a
moratorium on the use of genetic data to control access
to life insurance, at the same time that legislative efforts
were proposed to reduce the risks of genetic discrimi-
nation in access to health insurance and jobs (Committee
on Genetic Screening 1994, pp. 86–87). In industrial
countries, there is a strong tendency to reduce risk shar-
ing in health insurance and social security systems. This
tendency will cause an even greater increase in insurance
companies’ awareness of risk differentiation based on
outcomes of genetic tests (Pokorski 1995; Bodmer
1996).
In view of these nearly global developments, appro-
priate counseling on the social effects of taking a pre-
symptomatic test for a late-onset genetic disease, such
as a cancer syndrome or a neurodegenerative disorder,
has become a very delicate matter for clinical geneticists
(The Ad Hoc Committee on Genetic Testing/Insurance
Issues 1995). The silence of the majority of the insurance
companies in the U.S. study by Rodriguez-Bigas et al.
(1998) reflects the general neglect of this subject in dis-
cussions between the governments of the major eco-
nomic countries and the regulators of the international
insurance and underwriters system.
Families with these genetic risks may become bur-
dened by the unacceptable financial risks of the “wait
and see” attitude of the health and life insurance system
and the policy makers responsible for these regulations.
In Great Britain, life insurers recently started demanding
genetic-test results (Wilkie 1998).
Geneticists usually are held responsible for potential
adverse socioeconomic effects of genetic testing, by mak-
ing already foreseeable genetic risks more precise. How-
ever, from the onset of presymptomatic testing, society
and policy makers have been informed, by the genetics
community, of the need to formulate regulations based
on fairness and the prevention of genetic discrimination
(The Ad Hoc Committee on Genetic Testing/Insurance
Issues 1995).
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Reply to Niermeijer
To the Editor:
We thank Prof. Niermeijer for his response to and com-
ments on our letter to the editor, regarding health, life,
and disability insurance in hereditary nonpolyposis co-
lorectal cancer (HNPCC). As stated in our letter, our
survey respondents probably represented !5% of insur-
ance policies sold in the United States. We agree with
Prof. Niermeijer that “the silence of the majority of the
insurance companies in the U.S. study by Rodriguez-
Bigas et al. (1998) reflects the general neglect of this
subject in discussions between governments of the major
economic countries and the regulators of the insurance
and underwriter’s system.” However, we were encour-
aged to find, as stated in our earlier letter, that “the
majority of health, life, and disability insurance provid-
ers with an opinion would be willing to sell insurance
to HNPCC gene carriers and at risk-individuals” (Rod-
riguez-Bigas et al. 1998, p. 737). This apparent dichot-
omy in our survey reflects the need for legislative bodies,
insurance providers, health-care providers (including ge-
neticists and counselors), as well as members of affected
kindreds, to enter into dialogues so that further steps
can be taken for public and professional education, as
well as for prevention of genetic discrimination in our
societies.
Similar to what has occurred in the Netherlands, leg-
islative action has been undertaken in the United States,
with regard to potential genetic discrimination. The
Health Insurance Portability and Accountability Act of
1996, which went into effect on July 1, 1997, includes
provisions that deal with genetic discrimination as it
relates to the use of genetic information on individuals
who have or who are eligible for health insurance under
a group health plan offered by an employer. Under this
law, genetic information is included in the list of “health
status-related factors” that an insurer is prohibited from
using to deny, cancel, or refuse to renew insurance cov-
erage. The law also states that genetic information may
not be treated as a preexisting condition, without a di-
agnosis of the condition related to this information. An-
other provision provides that the health status of an
individual or his or her dependents cannot be used to
charge premium rates different from those applied to
other, similarly situated individuals within the group.
Although this law addresses some potential health in-
surance–discrimination concerns, it does not apply to
individuals ineligible for group health-insurance policies.
Furthermore, this law does not restrict the use of indi-
vidual genetic information for the purpose of setting a
particular group premium. These “gaps” in protection
demonstrate that, although legislation such as this has
been enacted, all issues related to potential health-in-
surance discrimination regarding individuals affected
with and/or at risk for genetic conditions such as
HNPCC have yet to be remedied. There is ongoing ac-
tivity, on both the federal and the state levels, to address
these “gaps” and other societal issues associated with
genetic status. In the meantime, it is the policy at our
institution, as it is in many other centers in the United
States and elsewhere, to provide risk assessment and ge-
netic consultation in order to address the exact issues
raised by Prof. Niermeijer.
MIGUEL A. RODRIGUEZ-BIGAS,1, MARY-
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Services, Roswell Park Cancer Institute, Buffalo
Reference
Rodriguez-Bigas MA, Vasen HFA, O’Malley L, Rosenblatt
M-JT, Farrell C, Weber TK, Petrelli NJ (1998) Health, life,
and disability insurance and hereditary nonpolyposis colo-
rectal cancer. Am J Hum Genet 62:736–737
Address for correspondence and reprints: Dr. Miguel A. Rodriguez-Bigas, Di-
vision of Surgical Oncology, Roswell Park Cancer Institute, Elm & Carlton
Streets, Buffalo, NY, 14243. E-mail: mrodriguez@SC3101.med.buffalo.edu
q 1999 by The American Society of Human Genetics. All rights reserved.
0002-9297/99/6401-0048$02.00
